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Forward 
One of the requirements for the degree of Doctorate in Clinical Psychology, is to complete a 
research portfolio, comprising of a systematic review and a Major Research Project (MRP). 
The MRP is a study that the student develops, conducts, and then formally reports on, over the 
course of the 3-year degree.   
Due to the COVID-19 pandemic and restrictions in participant recruitment, I was unable to 
proceed with my proposed MRP. In its place, this thesis contains my original MRP proposal, 
which has been updated and expanded to include a more detailed plan of how I would have 
analysed my MRP data, had the study gone ahead, as well as a brief critical appraisal of my 
planned methodology. My original MRP proposal, prior to changes, is in Appendix 4. 
In place of the MRP, this thesis also contains a brief report analysing secondary data from a 
previous study that explored mental health prevalence in students. One of my supervisors, Dr 
Maria Gardani, was a co-author of this study and provided access to the original database for 
secondary analysis. The brief report explores insomnia and its correlates in a student 
population, which shares some similarity with my original MRP topic. It also focused on 
insomnia, albeit, within a stroke population.  
The topic for the Systematic Review remained unchanged. 
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Abstract 
Background: Older adults tend to experience greater sleep related difficulties compared to 
younger adults. Despite this, non-pharmacological treatment options for insomnia, specifically 
tailored for the older adult population, have been somewhat under researched. This study 
systematically reviews evidence regarding the efficacy of Cognitive Behavioural Therapy for 
Insomnia (CBTI) within this age group. 
Method: Five databases were searched and reference lists of obtained articles were hand 
searched. Seven studies were identified and rated using a modified version of the Clinical Trials 
Assessment Measures. 
Results: Three papers were ranked as high quality, three as medium and one as low quality. 
Based on sleep diary outcomes, most participants experienced a significant improvement 
across sleep domains, post CBTI and at follow up, with four out of five studies reporting this. 
There were mixed results on the efficacy of CBTI on standardised outcome measures for 
insomnia and finally, two out of five studies found significant improvements post CBTI and at 
follow up, on actigraphy/polysomnography outcomes. There were key limitations across most 
papers including lack of randomisation to groups and convenience sampling.    
Conclusion: Sleep diary outcomes suggest participants experienced a significant improvement 
in symptoms of insomnia post CBTI, with these improvements mostly maintained at follow 
up. Although this was somewhat supported on objective measures of sleep, the evidence was 
not as strong. Future research should focus on improving methodological quality. 
MeSH terms and keywords: 
Cognitive Behavioural Therapy, Sleep Initiation and Maintenance Disorders, Insomnia, 
Aging, Older Adults  
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Introduction 
Insomnia: Definition and Prevalence 
According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5; 
American Psychiatric Association, 2015) insomnia is a sleep-wake disorder, characterised by 
difficulty in initiating sleep, staying asleep or early morning awakening. As a result, individuals 
often experience day-time sleepiness, irritability, and difficulties with concentration. Adults 
over the age of 65, tend to experience more sleep related difficulties than their younger adult 
counterparts (Sateia, et al., 2017). Specific sleep problems often experienced by older adults 
include, reduced sleep efficiency, frequent night-time wakening and delayed sleep onset 
(Lichstein et al., 2013). Age related circadian cycle changes such as feeling more awake first 
thing in the morning can account for these sleep changes to some extent, in addition to older 
adults being more likely to experience physical health complaints (Ludwin, Bamonti & 
Mulligan, 2018).  
Prevalence estimates of insomnia amongst older adults range from 9% to 25% (Brewster, 
Riegel & Gehrman, 2018). There is a common belief  in society that ‘older adults require less 
sleep’ (Ancoli-Israel., 1997) and therefore when an older person voices a sleep difficulty, it 
may be viewed as a normal part of aging (Martin, Shochat & Ancoli-Israel, 2000). This view 
seems to be unfounded, with studies suggesting that although older adults may find it more 
difficult to achieve satisfactory sleep; their sleep needs are very similar to that of younger adults 
(Ludwin et al., 2018).  
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Insomnia Definition and Measurement 
DSM-5 was released in 2013 and a major change from DSM-4, is the removal of the distinction 
between primary and secondary insomnia. This distinction was made to differentiate ‘pure’ 
independent insomnia from ‘secondary’ insomnia, whereby the insomnia occurs due to another 
mental or physical health condition. The removal of this distinction was due to a lack of 
evidence that treatment of the primary non-sleep disorder in turn, alleviates insomnia (Riemann 
et al, 2017).  
Standardised outcome measures using self-report have been validated for assessing insomnia 
including; the Insomnia Severity Index (ISI; Bastien et al., 2001) and the Sleep Condition 
Indicator (SCI; Espie et al., 2014). Standardised outcome measures that are based on diagnostic 
criteria, are an easy and cost-effective method of collecting information and measuring 
treatment effects (Morin et al., 2004).  
Objective measures of sleep such as polysomnography and actigraphy, are frequently used to 
obtain information on sleep/wake cycles. Polysomnography involves attaching electrodes to 
the body to monitor brain waves, breathing and movement. It is commonly used to diagnose 
sleep disorders (Sadeghniiat-Haghighi, Yazdi & Firoozeh, 2014).  Actigraphy involves 
measuring movement over an extended period using a non-intrusive device, usually worn on 
the wrist. Actigraphy devices correlate highly with polysomnography (r=0.71) (Morgenthaler 
et al., 2007). 
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Interventions for Insomnia 
Pharmacological Interventions 
Treatments for older adult insomnia, have historically focussed on medication, predominantly 
non-benzodiazepine hypnotics, opiates, and SSRI’s. Although helpful in the short term in 
reducing symptoms of insomnia, pharmacological interventions have not been found useful in 
the long term (Morin et al., 2004). Additionally, as the most used sleep medications are 
benzodiazepines, there is risk of dependency (Ludwin et al., 2018). 
Cognitive Behavioural Therapy for Insomnia (CBTI) 
CBTI has comparable short-term and long-term benefits to medication and is now 
recommended as the preferred treatment option for insomnia (Sateia et al., 2017). CBTI 
components with the strongest evidence base for efficacy include, stimulus control, cognitive 
restructuring, relaxation training and sleep restriction (Brewster et al., 2018). To be considered 
a CBTI intervention, at least two components should be included (Morin et al., 2004). 
Numerous studies report positive outcomes for CBTI in younger adults (Ludwin et al., 2018: 
Wagley et al., 2012) and although considerably fewer in number, promising outcomes for the 
efficacy of CBTI in older adults have been reported (Morin et al., 2004: Alessi et al., 2016). 
The most recent systematic review evaluating the efficacy of CBTI for older adult insomnia 
(Alessi et al., 2015) considered the efficacy of all non-pharmacological treatments for primary 
insomnia. They found moderate evidence in support of CBTI and weak evidence for bright 
light therapy and exercise.  This review appeared to follow DSM-4 classification guidelines, 
whereby it only evaluated the efficacy of CBTI in the context of primary insomnia, excluding 
all secondary insomnia papers. It concluded that CBTI significantly improved sleep compared 
to no treatment. 
12 
 
Aims 
This systematic review aims to update Alessi et al (2015) by reviewing papers published since 
their search in May 2014. Given that Alessi et al (2015) found weak evidence for bright light 
and exercise therapy it will only explore the efficacy of CBTI - the preferred treatment option 
for older adult insomnia (Sateia et al., 2017). Additionally, this review will follow DSM-5 
classification guidelines for insomnia and therefore unlike Alessi et al (2015) will not exclude 
studies exploring secondary insomnia. Finally, it will only include studies with a treatment 
control arm and will explore the efficacy of CBTI on areas of sleep most impacted within the 
older adult population, namely, sleep efficiency (SE), sleep onset latency (SOL) and wake after 
sleep onset (WASO). Focusing solely on the efficacy of CBTI in older adults and on papers 
published since Alessi et al (2015) will provide an updated, more focussed and detailed 
exploration compared to that of a broader review, exploring numerous treatment options, across 
a larger time frame.  
Research Questions 
1. Is CBTI more effective in improving SE, SOL and WASO, compared to a control 
condition? 
2. Is CBTI more effective in improving overall sleep quality and reducing insomnia 
severity symptoms compared to a control condition? 
 
Methods 
 
Search Strategy 
PRISMA guidelines were followed throughout this systematic review. An electronic search of 
the following databases was conducted: Medline, Embase, CINAHL, PsychInfo and 
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ScienceDirect. Searches were limited to papers published in English between 1st May 2014 and 
14th January 2020. Initial scoping searches were conducted to identify relevant search terms 
and these were finalised following discussion with a librarian (Appendix 1.2). Reference lists 
of selected articles were hand searched to identify other potential studies.   
 
Study Selection 
Duplicates were removed using RefWorks software. Titles and abstracts were screened, and 
eligible papers were then selected for full article review. The inclusion and exclusion criteria 
in Table 1 were used at each step in the review. 
 
Table 1. Inclusion and exclusion criteria 
Inclusion Exclusion 
• Published in English in a peer reviewed 
journal  
• Average age of participants is 65 years or 
over  
• Papers comparing the efficacy of CBTI to 
control condition 
• Participants meet DSM-5 diagnostic 
criteria for insomnia  
• Participants received a CBT intervention, 
comprising of at least two CBTI 
components: stimulus therapy, sleep 
restriction, relaxation training and 
cognitive restructuring.  
• Papers published after 14 May 2014 
• Studies focussing on medical risk factors or 
prevalence of insomnia  
• Average age of participants is less than 65 years 
or average age is not provided 
• Studies including participants with cognitive 
impairment 
• Studies with no control arm  
• No measurement of the efficacy of CBTI 
• No outline of which CBTI components (minimum 
of 2) were incorporated into the intervention 
• Review papers  
• Case studies 
• Book chapters 
• Conference abstracts 
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• Reports 
 
 
Data Extraction 
An extraction tool was developed and piloted to ensure significant information from each 
article was collected (see Appendix 1.3). The search, screening and data extraction was 
conducted by the first author alone.   
 
Quality Rating Scale & Criteria 
The quality of included studies was rated using a modified version of The Clinical Trials 
Assessment Measure (CTAM; Tarrier & Wykes, 2004). The CTAM has high internal 
consistency (Cronbach α = 0.697) and external validity (p =.93, P <.001) (Wykes et al., 2007), 
and was developed by extracting key features from CONSORT (CONsolidated Standards of 
Reporting Trials) which were designed to improve reporting of randomised control trials and 
to allow readers to evaluate with ease, the quality and validity of studies (Schulz, Altman & 
Moher, 2010). Ratings of 0, 1, 3, 4, 5, 6 or 10 can be allocated for each item. For this review, 
the CTAM was altered to include items specific to the measurement of insomnia and the 
efficacy CBTI. The modified CTAM consisted of 26 items covering six areas of trial design, 
with a maximum score of 147 being available (see Appendix 1.4). Items and subsequent ratings 
were weighted according to their relevance to the research questions. A score of 72 or less out 
of 147 (49%), was considered low quality. A score of between 73 and 109 (50-74%) was 
considered moderate quality and a score of 110 (75%) or more was considered high quality. 
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A Clinical Psychologist, unrelated to the study and with experience in systematic review 
methodology and paper quality rating, was given the list of papers meeting the inclusion criteria 
to review quality, for inter rater reliability purposes. They randomly selected three of these 
papers and scored them against the CTAM. Agreement of final scores on the CTAM was high 
96% and therefore it was deemed unnecessary to co-rate additional studies. Differences in 
ratings were resolved via discussion. 
 
Results 
Study Selection 
The literature search produced 2534 papers, with the removal of duplicates leaving 1984. The 
titles of the remaining articles were compared to the inclusion and exclusion criteria, excluding 
1866. The abstracts of the remaining 118 articles were compared to the inclusion and exclusion 
criteria leaving 34 papers deemed suitable for full text review and following this, 7 papers were 
considered eligible for inclusion. Hand searches of references identified one paper.  Figure 1 
outlines the paper selection process. 
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Figure 1: PRISMA Flow diagram showing the details of the systematic search process 
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Results 
Table 2: Summary of studies included in the systematic review, including overall percentage achieved on the CTAM. A breakdown of scores for 
each study, across all 6 CTAM subscales, can be found in Appendix 1.5. 
Study, 
Country & 
Quality 
rating 
Sample 
Characteristics 
 
Description of Intervention 
(N=Participant Number) 
Areas of sleep 
measured, and 
outcome measures 
used 
Effect Sizes/ Statistical Outcomes 
1. McCrae et 
al (2018) 
 
 
USA 
 
79% - High 
 
62 participants 
 
68% females 
 
Age range: 65+  
(Mean = 69.4, 
SD = 7.72). 
 
 
RCT (2 groups) 
 
BBTI (N=32) – consisting of relaxation, 
stimulus control, sleep hygiene and sleep 
restriction 
 
SMC (N=30) – social conversation & sleep 
diary completion 
 
Groups delivered one to one across 4, weekly, 1-
hour sessions  
 
Data recorded at baseline, post treatment and 3 
months 
 
SOL, WASO, SE, 
 
Sleep Diaries 
Actigraphy 
 
 
Sleep Diaries 
BBTI vs SMC 
SOL - Significant difference post treatment d = 
0.26, 3 months d = 0.18 
SE - Significant difference post treatment d = 0.14, 
3 months d = 0.23 
WASO - Significant difference post treatment d = 
0.16, 3 months d = 0.32 
 
Actigraphy 
BBTI vs SMC 
No significant difference in WASO, SOL, or SE 
post treatment or at 3 months follow up.  
 
2. Alessi et al 
(2016) 
 
76% - High 
159 participants  
 
97% males 
 
RCT (3 groups) 
 
SOL, WASO, SE,  
 
Sleep diaries 
Actigraphy 
Sleep Diaries 
CBTI vs SEC 
SOL - Significant difference post treatment   
d= -0.55 6 months d = -0.37 & 12-months d = -0.41 
18 
 
 
USA 
Age Range: 60+  
(Mean = 72.2, 
SD = 7.7) 
CBTI (delivered one to one, N=53) – cognitive 
therapy, stimulus control, sleep hygiene and 
sleep restriction 
 
CBTI (delivered in a group setting, N=52) – 
content as above 
 
SEC (N=54) – one to one format, sleep 
education 
 
All groups received 5 weekly, 1-hour sessions.  
 
Data recorded at baseline, post treatment, 6 
months & 12 months 
 
Group and individual CBTI results were 
combined  
PSQI 
ISI 
 
WASO - Significant difference post treatment  
d= 0.36 but NOT at 6 months d = -0.21- or 12-
months d = 0.04 
SE - Significant difference post treatment d= 0.68, 
6 months d = 0.43 & 
12 months d = 0.35 
 
Actigraphy 
(only SE outcomes) 
No significant difference in SE between groups, 
post treatment or at 6 or 12 months 
 
SQ & Insomnia Severity  
Between Groups 
PSQI - Significant differences post treatment 
d=0.98, 6 months d= 0.69, 12 months d = 0.63 
ISI - Significant differences post treatment d = 
0.85, 6 months d = 0.74, 12 months d = 0.54 
 
3. Irwin et al 
(2014) 
 
76% - High 
 
USA 
123 participants 
 
72% female 
 
Age Range: 55 - 
85 
(Mean Age = 
65.7, SD = 6.1)  
 
RCT (3 groups) 
 
CBTI (N =50) - stimulus control, relaxation, 
mood enhancement and sleep restriction  
 
TCC (N=48) – movement therapy 
 
SS (N=25) - education on sleep and ageing 
 
SE, WASO, SOL 
 
Sleep diaries 
Polysomnography  
PSQI 
Sleep Diaries 
CBTI vs SS** 
SE - Significant difference at 4 months d = 3.12- 
and 16-months d = 2.31 
SOL - Significant difference at 4 months d = 2.33- 
and 16-months d = 2.52 
WASO - Significant difference at 4 months d = 
3.48- and 16-months d = 2.25 
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2-hour weekly sessions, in groups of 7 – 10 
participants, over 4 months 
 
Data recorded at baseline, 4, 7 and 16 months 
Polysomnography 
(only 4 months follow up) 
 
CBTI vs SS 
No Significant difference for SE, WASO or SOL 
Pre vs 4 months d = 0.14 
 
SQ & Insomnia Severity  
PSQI** 
CBT vs SS 
Significant differences at 3 months d = 0.79 and 
16-months d = 0.81 
 
 
4. Martin et al 
(2017) 
 
69% - 
Medium 
 
USA 
42 participants 
 
93% males 
 
Age Range: 60+ 
(Mean age = 
77.1, SD = 9.9)  
 
 
 
RCT (2 groups) 
 
 SIP (N=21) – sleep hygiene, sleep restriction, 
stimulus control 
 
 IC (N=21) – information on age and sleep  
 
Both groups received one to one, 4, weekly, 45-
minute sessions 
 
Data recorded post treatment and at 4 months 
 
SE, WASO 
 
ISI 
PSQI 
Actigraphy 
Actigraphy 
SIP vs IC 
SE: Significant difference post intervention 
(p=0.007) and at 4 months (p=0.02) 
 
WASO: Significant difference post intervention 
(p=0.02) and at 4 months (p=0.03) 
 
SQ & Insomnia Severity  
Between Groups 
 
PSQI: No significant difference post treatment or 
at follow up 
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ISI: No significant post treatment or at follow up 
 
Effect sizes could not be calculated  
 
5. Tanaka et 
al (2019) 
 
63% - 
Medium 
 
Japan 
 
49 participants 
 
73% females 
 
Age Range: 
unknown  
(Mean age = 
69.7, SD = 8.1)  
 
 
 
RCT (2 groups) 
 
CBTI (N= 23) – stimulus control, sleep hygiene, 
sleep restriction, education, relaxation 
 
WLC (N=23) – completed PSQI at baseline and 
follow up 
 
4 weekly sessions, (one 60-minute group 
session, one 45-minute individual session and 
two 20 minutes follow up)  
 
Data collected at baseline and 3 months  
 
 
Sleep quality 
 
PSQI 
SQ – PSQI 
CBTI vs WLC** 
No Significant differences at 3 months p=.16, d= 
0.22 
 
 
6. Sadler et al 
(2018)  
 
62% - 
Medium 
 
Australia 
72 participants 
 
56% females 
 
Age Range: 65+ 
(Mean age = 75, 
SD = 7.0)   
 
 
RCT (3 groups) 
 
CBTI (N=24) – stimulus control, sleep 
restriction, sleep hygiene and relaxation 
 
CBTI+ (N=25) – as above but with the addition 
of depression specific strategies 
 
SOL, WASO, SE 
 
Sleep Diaries 
ISI 
 
 
 
Sleep Diaries 
CBTI vs PCG 
SOL: Significant difference at 8 weeks d = 1.85 
but not at 20 weeks. 
SE: Significant difference at 8 weeks d = 1.85 but 
not at 20 weeks.  
WASO: Significant difference at 8 weeks d = 1.02 
but not at 20 weeks. 
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PCG (N=23) – education on sleep, insomnia and 
depression 
 
All groups received, 8, weekly, 60-90-minute, 
group sessions 
 
Data collected at baseline, 8 weeks and 20 
weeks  
 
SQ & Insomnia Severity  
ISI 
Significant difference at 8 weeks, d= 1.87 and at 
20 weeks d= 2.40 
 
7. Dolu et al 
(2018) 
 
46% - Low 
 
Turkey 
 
 
52 participants  
 
52% females 
 
Age Range: 65 - 
96 
(Mean age = 
79.8, SD = 7.4) 
 
 
 
(Non RCT) - Participants allocated to either: 
 
SP (N=26) – sleep restriction, sleep hygiene, 
stimulus control, education. Participants 
received 4, weekly, one to one, 1-hour sessions 
  
TAU (N=26) - participants received regular 
nursing services 
 
 
Data collected at baseline, 8 and 12 weeks 
SOL, SE, WASO 
 
Sleep diaries 
PSQI 
Actigraphy 
 
 
Sleep Diaries 
SP vs TAU 
SOL – No significant difference 8 weeks d = < 30 
or at 12 weeks d = >50 
WASO – no data provided 
SE - No significant difference at 8 weeks d = <30 
or at 12 weeks d = >80  
 
Actigraphy 
SP vs TAU 
SOL - No significant difference at 8 weeks d = <30 
or at 12 weeks d = <30  
SE - Significant difference at 8 weeks d = >80 and 
at 12 weeks d =>30  
WASO - No significant difference at 8 weeks d = 
<30 but a significant difference at 12 weeks d = 
<30  
 
SQ  
22 
 
Between Groups 
PSQI - No significant difference at 8 weeks d = 
<30 or 12 weeks d = (0.50 – 0.79)  
 
 
 
 
 
 
KEY: PSQI = Pittsburgh Sleep Quality Index; SE = sleep efficiency; WASO = wake after sleep onset; SOL = sleep onset latency; BBTI = brief behavioural 
treatment for insomnia; CBTI = cognitive behavioural therapy for insomnia; SMC = sleep monitoring control; SEC = sleep education control; TCC =  tai-chi 
chih; SS = sleep seminar; SIP = sleep intervention programme; IC = information control; SQ = Sleep Quality; PEC = psychoeducation control; WLC = waiting 
list control; SP = sleep programme; TAU = treatment as usual; ISI = insomnia severity index ** = effect size calculations completed by author of this review 
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Brief Summary of Individual Studies 
‘High quality’ papers 
McCrae et al (2018) – 79% 
This study examined the effects of a BBTI on symptoms of insomnia, mood, and cognitive 
functioning. A power calculation took place prior to recruitment with the study achieving the 
intended participant numbers. Participants were recruited via community advertising and had 
a very high level of education attainment, with 60% having at least 16 years of education. The 
randomisation process to group allocation was not described. CBT training for therapists was 
not clearly described and the follow-up period was short (3 months). The BBTI intervention 
was manualised and described in sufficient detail for replication. 16% of participants dropped 
out before the end of the intervention and a further 13% were lost to 3 follow-up. Baseline 
insomnia duration was significantly different between groups and was controlled for with 
ANCOVA.   
   
Alessi et al (2016) – 76% 
This study evaluated the efficacy of a new CBTI programme designed for use by non-sleep 
clinicians. A power calculation suggested a sample of at least 150 participants would be 
required to test for significant differences (power = 80%). A strength of this study was its 
randomisation process, which was carried out independently and clearly documented. 
Therapist training comprised of attending either a 2-day workshop on CBTI or 6 CBTI webinar 
sessions, of which the length and content was unclear. The intervention was manualised but 
lacked sufficient detail to be replicated. It was not clear if outcome assessments were completed 
24 
 
by independent assessors. All participants who commenced the intervention were included in 
the final analysis.  
 
Irwin et al (2014) – 76% 
This study investigated the efficacy of CBT vs Tai chi chih vs a sleep control group in reducing 
symptoms of insomnia, depression, and inflammation. Participants were recruited via 
community advertising. The study scored full marks for ‘allocation’, offering a clear account 
of the randomisation process. It was not clear whether assessments were carried out by 
independent assessors and similarly, although assessments were carried out blind, the 
procedure was not documented. The manualised intervention was not described adequately to 
replicate. Therapists were suitably trained to deliver CBTI and adherence to treatment protocol 
was measured via observations. Subject retention for the CBTI group was high.  
 
‘Medium quality’ papers 
Martin et al (2017) – 69% 
The aim of the study was to determine the efficacy of a sleep intervention programme compared 
to an information only control among older adult veterans. The randomisation process was not 
described, and assessments were carried out by assessors not involved in the study.  The CBT 
intervention was appropriate, manualised, and clearly described for the purposes of replication. 
Participant retention was high and an intention to treat analysis was documented. Therapist 
adherence to the treatment protocol was monitored, via frequent supervision and direct 
observations.  
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Tanaka et al (2019) – 63% 
This study aimed to determine whether brief CBTI could reduce symptoms of insomnia and 
depression in older adults. Randomisation was carried out by an independent researcher 
however it was unclear who completed outcome assessments. Similarly, the CBT intervention 
was well documented however the intervention was not manualised and delivery open to 
interpretation. CBT training was insufficient with therapists attending a ‘2-day CBT training 
course’.  
 
Sadler et al (2018) – 62% 
The study aimed to establish whether CBTI was effective in reducing symptoms of insomnia 
and depression in older adults. Participants were community mental health team attendees. A 
power analysis was completed however the study failed to recruit the number of participants 
set out. A strength of this study was its allocation procedure, which was carried out by an 
independent researcher. No intention to treat analysis was documented and therefore it was 
unclear whether all randomised participants were included in the analysis. The detailed, 
manualised CBTI intervention was carried out by therapists who had at least 1 years’ 
experience. Therapist adherence to treatment protocol was suitably monitored.  
 
‘Low quality’ papers 
Dolu et al (2018) – 46% 
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This non-randomised study investigated the effects of a sleep programme for insomnia and 
depression in care home residents. Educational attainment was high amongst participants, with 
around 80% obtaining high school education or higher. It was unclear who conducted outcome 
assessments and therefore open to potential bias. The paper did not outline whether the sleep 
programme was manualised and its means of measuring fidelity to treatment were not adequate. 
The intervention was described in enough detail for replication. Nurse’s previous CBT 
experience was not documented. Although the participant drop-out rate was low, an intention 
to treat analysis was not completed.  
Overall Findings 
All but one study (Dolu et al, 2018) found significant reductions in insomnia post intervention 
on at least one sleep outcome measure. The difference in findings by Dolu et al (2018) could 
potentially be attributed to a quality problem, since it was rated lowest quality overall or could 
also be related to other factors including 1) it being the only study to use care home residents 
as participants and whom therefore may respond differently to CBTI and 2) it had the highest 
mean age of participants of all studies (79 years) and possibly older participants may not 
respond as well to CBTI. Effect sizes post treatment varied from small to large across studies 
and similarly at follow up. Martin et al (2017) acknowledged that their study was underpowered 
to detect any meaningful change although recorded significant improvement post intervention 
on actigraphy data. This was the only study, other than Dolu et al (2018) to find any significant 
post intervention effects on actigraphy devices. 
Although some studies had a significantly higher ratio of males or females in their participant 
sample e.g. Alessi et al (2016) had 97% males, when combined there was a general gender 
balance across reviewed studies, with no gender and outcome trend evident between studies. 
Those studies finding significant effects at follow up (McCrae et al, 2018; Alessi et al, 2016 & 
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Irwin et al, 2016) tended to have a younger mean age of participants. Additionally, Martin et 
al (2017), Sadler et al (2016) and Dolu et al (2018) had a higher mean age of participant samples 
and also had a significantly higher proportion of participants either residing in assisted living 
accommodation or in a care home environment.   
Follow up periods ranged between two and sixteen months with no apparent relationship 
between length of follow up and effect size observed. Additionally, each study had a 
considerably high ratio of white participants, ranging from 71% to 83%. 
Overall, there were differences across studies in how outcomes were measured. Some studies 
used three modes of measurement whilst others used only one and therefore as a result direct 
comparison of specific outcomes between studies is limited. 
 
Discussion 
Although the number of studies published since the Alessi (2015) review is modest, the 
findings of this systematic review support the use of CBT and its components for older adult 
insomnia. Compared to treatment as usual and sleep seminar control groups, CBTI improved 
1) sleep efficiency 2) wake after sleep onset and 3) sleep onset latency in 4/5 studies using 
sleep diaries. Of the four studies finding positive treatment effects on sleep diaries, three were 
of high quality on the CTAM which increases the confidence of these findings.  
Of the five studies that used polysomnography and actigraphy as outcomes, only two studies 
(Martin et al, 2017; Dolu et al, 2018) found significant change in sleep efficiency post CBTI 
and these were of medium and low quality.  The study by Martin et al (2017), which was 
lacking in statistical power, found significant reductions in wake after sleep onset and neither 
study reported significant treatment effects for sleep onset latency post CBTI. Given that only 
2/5 studies found significant treatment effects across some but not all sleep domains on 
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actigraphy/polysomnography outcomes, the efficacy of CBTI was much smaller on objective 
measures compared to subjective measures.   
There was variation across studies on sleep quality and insomnia severity outcomes post CBTI. 
Two high quality studies (Alessi et al, 2016; Irwin et al, 2014) found a significant reduction in 
PSQI scores post treatment. A third, medium quality study (Tanaka et al, 2019) found no 
significant difference pre to post treatment. Similarly, two out of three studies (Alessi et al, 
2016; Sadler et al, 2016), which were of high and medium quality respectively, found a 
significant reduction in ISI scores post treatment. The study that found no significant difference 
(Martin et al, 2017) was of medium quality. As significant treatment outcomes were found on 
the PSQI and ISI on 4/6 occasions, and by some high-quality papers, the findings overall 
support the efficacy of CBTI in older adults. 
 
Overview of Methodology 
With regards to participant samples, five studies used a convenience sample, with three of these 
studies inviting participants to respond to community advertisements. Participants who 
volunteer to participate in health-related studies are more likely to be female, highly educated, 
of higher socio-economic status and more interested in health and wellbeing (Salkind, 2010) 
and hence, may not have been representative of the general population.  
Control groups were included in all studies comprising a mixture of treatment as usual (TAU) 
controls who received no additional input and sleep education/seminar ‘active’ control groups 
who received information around sleep. Unlike TAU, active control groups control for 
improvements caused by factors other than the experimental treatment itself, making them the 
methodologically stronger option. When both groups have similar expectations of 
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improvement, active control groups control for possible placebo effect related improvements 
(Boot et al, 2013). Additionally, since participants engage in tasks during the intervention 
period, usually with a therapist, improvements solely due to a strong therapeutic relationship 
are also controlled for (Leahy, 2008).  
Only two studies included a follow up of at least 6 months (Alessi et al, 2016; Irwin et al, 
2014), both of which were of high quality and found maintenance of improvements across most 
sleep domains at 6, 12 and 16 months follow up, providing support for longer-term benefits of 
CBTI.  
Five studies followed manualised protocols, increasingly the likelihood of consistency and 
reliability that the intervention itself was accountable for treatment effects. Only 3 studies 
provided enough information for studies to be replicated, making it difficult to repeat studies 
and test reliability of results. Moreover, only 3 studies cited adequately trained therapists for 
intervention delivery, with the remaining studies either not providing enough information on 
therapist background or not stipulating whether therapists had CBT specific qualifications. This 
raises questions about the validity of the interventions as CBT. 
Findings of this review are like those by Alessi et al (2015) who on the basis of sleep diaries, 
found moderate quality evidence for the efficacy of CBTI in older adults for SE, SOL and 
WASO. Of the seven CBT studies reviewed by Alessi et al (2015), only one study provided an 
effect size for the CBT intervention and therefore the overall magnitude of the effect was 
unclear. This is considerably different to the present review where six of the seven included 
studies either reported or offered enough information to calculate effect sizes, with large effects 
being found across some high-quality studies and subsequently offers further support for the 
efficacy of CBTI amongst older adults. Alessi et al (2015) did not review 
actigraphy/polysomnography measures. An earlier review (Montgomery & Dennis, 2004) 
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considered both objective and subjective measures and overall found support for the efficacy 
of CBTI, as in the present review. Montgomery and Dennis (2004) also found inconsistency 
between subjective and objective measures; participants tended to report greater improvements 
on subjective rather than objective measures of sleep, post CBTI intervention. These findings 
are consistent with those by Morin, Cuthbert & Schwartz (1994), who discussed that the 
magnitude of perceived sleep improvement often tends to be greater in subjective measures.  
The findings of this review are similar to those studies carried out within a younger adult 
population. Trauer et al (2015) carried out a meta-analysis on the efficacy of CBTI in younger 
adults. They found similar results to this review where evidence supported the efficacy of CBTI 
with moderate effects, across sleep domains. Similar to the older adult population, the 
magnitude of effects tended to be greater on subjective measures amongst younger adults. 
The efficacy of CBTI found in this review is at least equal to or superior to outcomes found for 
pharmacological treatments amongst older adults. A meta-analysis by Glass et al (2005) found 
sedative use to significantly improve sleep in older adults but identified the magnitude of 
effects to be small. Additionally, they found that individuals receiving sedatives were 
significantly more likely to experience an adverse event e.g. falling. Given the risks associated 
with pharmacological interventions, CBTI may be a preferable treatment option within this 
population. 
Strengths and Limitations of this Review   
This is the first study to systematically review CBTI in an older adult population since Alessi 
et al (2015). A recognised quality assessment tool for methodological evaluation was used to 
identify strengths and weaknesses within the literature. The method by which studies were 
evaluated in this review, is subjective in nature and therefore open to differing interpretations 
and possible bias, despite the inclusion of an independent rater. Additionally, the inclusion of 
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second raters at the screening and data extraction stages would have increased reliability of 
results obtained.  
Suggestions for future research 
Further studies are needed to strengthen the evidence base and should 1) include longer follow 
up periods to establish the long term efficacy of the CBTI intervention and whether 
improvements in symptoms were maintained  2) carry out randomisation independently of the 
research team to eliminate possible bias in group assignment and enhance reliability of results 
found 3) ensure outcome assessments are marked blind and independently, to minimise 
potentially bias scoring 4) include adequately trained therapists to increase likelihood of 
fidelity to the evidence base and validity of results obtained 5) should recruit participants from 
a wider population to increase generalisability of results obtained  6) use active controls to 
increase the likelihood that changes observed were due to the intervention and not placebo or 
other confounding effects. 
Conclusion 
Despite participants experiencing a subjective improvement in sleep, evidence for this on 
objective measures is weak. Methodological limitations in the literature, in relation to 
CONSORT guidelines (Schulz, Altman & Moher, 2010) prevent firm conclusions being made 
but given reports of improvement across most sleep domains post treatment and at follow up 
in several high quality studies, CBTI can tentatively be  recommended for older adult insomnia. 
 
For ‘Practice Points & Research Agenda’ see Appendix 1.6 
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Abstract 
Background: Insomnia is a frequently occurring post-stroke symptom, with approximately one 
third of sufferers experiencing sleep problems 12 months after stroke. Cognitive Behavioural 
Therapy (CBT), has been found to significantly reducing symptoms of insomnia within the 
general population. Few studies, however, have been carried out exploring the efficacy of 
psychological interventions for post stroke insomnia.  
Aims: This study aims to explore the efficacy of a brief behavioural treatment intervention for 
insomnia (BBTI) in reducing symptoms of insomnia, following a stroke. Additionally, it will 
aim to explore the retention and recruitment rate of participants. 
Methods: Participants (N=6) will be recruited from NHS Stroke Psychology Outpatient 
Services and from a local charity. The study will take the form of a multiple baseline ABA 
single case experimental design (SCED), whereby multiple measurements of participant sleep 
efficiency, sleep duration and sleep onset latency will be recorded during the baseline and 
intervention phases. Participants meeting the inclusion criteria will complete standardised 
outcome measures for sleep and mood before being randomly allocated to 1 of 6 differing 
duration baseline phases (ranging from 5 – 20 days). On completion of the baseline phase, 
participants will then complete the 4-week BBTI intervention. Finally, participants will 
complete a 7-day post-intervention baseline phase. Participants will be invited to complete 
sleep diaries throughout.  
Applications: Given the high incidence of post-stroke insomnia, if successful, the BBTI could 
help a large proportion of stroke survivors achieve more satisfactory sleep. Additionally, a 
larger scale research study, incorporating more participants, could be carried out in future.  
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Introduction 
 
Stroke & its Impact 
Stroke is a major public health concern, causing death and decreased quality of life in people 
of all ages (Chen et al., 2014). Ischemic stroke - the most common form, occurs when a 
blockage reduces blood flow to the brain causing damage to surrounding cells (Musuka, 2015). 
Haemorrhagic stroke - the next most common, involves blood from an artery bleeding into the 
brain (Rymer, 2011). The extent of brain injury caused depends on the location in which the 
blockage took place, total duration of blood starvation and the ability of neighbouring healthy 
cells to compensate for the damaged ones (Chen et al, 2014).  
 
Psychiatric Symptoms Post Stroke 
Meta-analysis suggests that one third of stroke survivors, experience post stroke depression 
(Hackett et al., 2005) and one quarter develop post stroke anxiety (Schottke & Giabbiconi, 
2015), with both disorders gaining research interest and consideration of potential treatment 
options (Rasquin., et al, 2009 & Broomfield et al., 2011). Sleep associated difficulties are also 
common post-stroke, with Kim et al (2017) identifying almost two thirds of patients to 
experience insomnia one-month after stroke. Similarly, Glozier et al (2017) found that 34% of 
patients, one-year post stroke, met the DSM-5 criteria for insomnia. As well as the distress of 
the symptom itself, insomnia has been identified as a risk factor for further stroke, suicide, and 
poorer recovery prognosis (Yang et al., 2017). Despite its high prevalence and impact, 
treatment for insomnia amongst stroke survivors has had little consideration. 
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Psychological Treatment for Insomnia 
There is a wealth of research supporting the efficacy of talking therapies for insomnia within 
the general population (Okajima, Komada & Inoue, 2011). Cognitive Behavioural Treatment 
for Insomnia (CBTI) has been reported to reduce symptoms of insomnia in 70-80% of patients, 
with long-term improvements documented (Okajima et al., 2011). CBTI has also been found 
to alleviate insomnia symptoms post intervention and at follow up, in the context of other health 
conditions including chronic pain (Jungquist et al., 2012), and heart disease (Conley & 
Redeker., 2015). Similar findings have been found surrounding stroke, with Nguyen et al 
(2017) carrying out a pilot RCT comprising of 15 participants, nine of which were randomised 
to a CBTI group and six to a TAU group. CBTI was found to reduce post stroke insomnia 
immediately after the intervention but not at four months follow up. To the author’s knowledge 
this is the only study that has explored the efficacy of CBTI for post stroke insomnia.  
Patients experiencing insomnia alongside a physical health condition may face multiple 
challenges that impact their ability to attend a traditional 6-8 session CBTI intervention. Troxel, 
Germain and Buysse (2012) developed a four session, manualised brief behavioural treatment 
for insomnia (BBTI) which may be more accessible to a wider group of individuals. BBTI is 
based predominantly on the behavioural components of CBTI principles, as outlined by the 
National Institute of Health (2005).  
 
This study will aim to deliver BBTI to participants experiencing post stroke insomnia. BBTI 
will be based on the protocol by Troxel et al., (2012) but tailored to match the needs of the 
stroke population, e.g. minimising falls risk in the night. Governing bodies state there should 
be a period of feasibility and pilot testing when developing complex treatment interventions 
(Medical Research Council, 2000). A feasibility study looking into the effectiveness of BBTI 
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following brain injury was carried out by Zouharova and Gardani (in preparation). This study, 
which took the form of a case series design, recruited nine participants and retained six. Four 
participants experienced “clinically significant sleep improvements”, one showed “treatment 
response” and one demonstrated “nonresponse”. The proposed study will follow similar 
research procedures as the feasibility study. 
 
Aims and Hypotheses: 
The primary aim of this study is: 
a) To explore change in participant sleep efficiency (SE), sleep onset latency 
(SOL) and sleep duration (SD), before, during and after BBTI, as measured by 
a series of sleep outcome measures and sleep diaries.  
b)  To explore the recruitment and retention rate of participants taking part in the 
study. 
The secondary aim of this pilot study is: 
a) To determine whether BBTI reduces participant symptoms of anxiety and 
depression. 
CBTI has been found to significantly reduce symptoms of insomnia in the wider population 
and in the context of physical health problems, including following a stroke. As BBTI includes 
behavioural components of CBTI, it is hypothesised that outcomes will be similar and 
participants receiving BBTI will experience a significant reduction in insomnia post 
intervention. 
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Additionally, given the recruitment and retention rates reported in the feasibility study by 
Zouharova and Gardani (in preparation), it is hypothesised that this study will have a high 
retention rate of participants.  
 
Methods 
Participants 
The study will recruit approximately 6 participants. Stroke induced disability, as measured by 
the Modified Rankin Scale (Farrell et al, 1991), will be recorded for each participant, with this 
information being obtained from patient records or medical provider, after patient consent has 
been obtained. For participants recruited via the non-NHS route, once patient consent has been 
sought, the researcher will contact the participant’s medical provider to obtain this information. 
 
Inclusion and Exclusion Criteria  
Inclusion Criteria: 
Eligible participants will have experienced an ischemic or haemorrhagic stroke at least 3 
months but fewer than 18 months prior to participating. This is because at least 3 months of 
sleep disturbance is required for a diagnosis of insomnia. Additionally, insomnia related to a 
historic stroke may respond differently to BBTI compared to insomnia related to a more recent 
stroke. Participants should be over 18 years of age and will meet the DSM-5 criteria for 
insomnia, with levels of insomnia being measured via the Sleep Condition Indicator (SCI; 
Espie et al, 2014). Participants experiencing other sleep disorders e.g. obstructive sleep apnoea, 
will be eligible to participate, if the disorder is effectively managed. Participants must exhibit 
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a good level of cognitive functioning to manage the demands of the study e.g. completing daily 
sleep diaries and this will be defined as a score of 8 or more out of 10 on the Mini-Montreal 
Cognitive Assessment (MMOCA; Mai et al 2013) at point of screening.  
 
Exclusion criteria: 
Exclusion criteria will include individuals with a diagnosis of dementia, epilepsy, an untreated 
psychotic illness, substance misuse, other neurological disorders and medications known to 
impact on sleep. Participants should not have received a previous course of cognitive 
behavioural therapy for post stroke insomnia. Additionally, people who are aphasic or unable 
to write will be unable to take part, due to the study requiring written information to be 
recorded. Individuals experiencing chronic pain, will not be able to take part in the study since 
chronic pain could interfere with the intervention and results obtained. Potential participants 
will be asked about current levels of pain and completion of the Pittsburgh Sleep Quality Index 
(PSQI; Buysse et al, 1989) will inform this. Individuals undergoing rehabilitation will not be 
eligible to participate in the study since rehabilitation often includes specific CBT for insomnia 
elements and subsequently could influence overall findings.  Finally, participants currently 
involved in other research will not be eligible to participate. 
 
Recruitment Procedures 
Participants will be recruited from a local charity and NHS Stroke Psychology Outpatient 
Services. 
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Charity recruitment:  
Charity recruitment: Study flyers (Appendix 2.1), offering a brief overview of the study will 
be displayed within Headway charity premises. The flyer will advise service users to contact a 
Headway staff member if they are interested in participating who will then provide them with 
a participant information sheet (Appendix 2.2). If the service user wishes to participate or 
receive more information about the study, they can contact the researcher by telephone, sending 
'the note of interest' slip attached to the information sheet or by asking a Headway staff member 
to make contact on their behalf. The researcher will then arrange to meet with the individual, 
either on charity premises or at the individual’s home to discuss the study further. 
 
NHS Recruitment: The researcher will present details of the study to NHS Stroke Psychology 
Outpatient Services. Staff will hand out participant information sheets to patients with 
symptoms of insomnia and who may be eligible to participate. Interested patients can contact 
the researcher in the same way as described for Headway service users. Once contact has been 
made, the researcher will arrange to meet the patient, either at Headway or in the patient’s own 
home, to discuss the study further.  
 
Consent and Measures 
At the initial meeting, discussion will take place on what participation involves, assessing 
individual suitability using the inclusion/exclusion criteria and answering queries throughout. 
If the individual wishes to proceed and they meet the criteria, written consent will be obtained 
(Appendix, 2.3). Consenting participants will complete several outcome measures including: 
the Pittsburgh Sleep Quality Index (PSQI, Buysse et al., 1989), the Sleep Condition Indicator 
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(SCI, Espie et al., 2014), the Mini-Montreal Cognitive Assessment (MMOCA, Mai et al., 
2013), the semi-structured sleep questionnaire (Gardani, et al., 2015), the Generalised Anxiety 
Disorder (GAD-7, Spitzer et al., 2006) and the Patient Health Questionnaire (PHQ-9, Kroenke 
& Spitzer., 2001). Further information on measures used can be found in Appendix 2.4. 
 Additionally, participant demographic information will be collected in the first meeting with 
participant co-morbid conditions documented. Self-reports will be verified via patient records 
or by the participant’s medical provider, following consent. 
Finally, participants will be provided with sleep diaries (Appendix 2.5) for completion 
throughout the duration of the study with demonstrations on their completion taking place. 
Sleep diaries will collate information on participant sleep onset latency, sleep efficiency and 
wake after sleep onset.  Participants will then be randomised to a baseline phase. The first day 
of the baseline phase will not commence until 24 hours after the initial meeting. Participants 
can choose to withdraw within these 24 hours or at any point of the study. 
 
Design & Research Procedures 
This study will take the form of a single case experimental design (SCED), aiming to recruit 6 
participants. At the end of the initial meeting, participants will be randomly allocated, using a 
random number generator (www.randomizer.org), to differing baseline durations (ranging 5 to 
20 days). Following the baseline phase, participants will then commence the intervention stage 
before finally returning to a post intervention, 7-day baseline phase. The intervention will be 
delivered across 4, weekly sessions. The first session will last approximately 1 hour and will 
take place at Headway or in the patient’s own home. The remaining 3 sessions will last 
approximately 20 minutes and be delivered over telephone. One more face to face session will 
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take place after the final baseline phase, to return sleep diaries and complete post intervention 
outcome measures. For an overview of the BBTI see Appendix 2.6. 
.  
Data Analysis 
Visual analysis of the data will be carried out, graphing the data collected and visually 
inspecting any differences between baseline and intervention phases. Historically, it was 
suggested that in SCED designs, visual inspection of the data demonstrated results that 
statistical tests failed to find (Bobrovitz & Ottenbacher., 1998). It has been acknowledged, 
however, that visual analysis alone provides some difficulties e.g. collating results for meta-
analysis and allowing for comparison (Tate et al., 2015). Although there is no consensus on 
which statistical procedure to use in analysing SCED data (Bobrovitz & Ottenbacher., 1998), 
the methods available tend to follow the same principle whereby they measure the extent of 
non-overlapping data between differing conditions. Tau-U analyses is one statistical method 
that controls for baseline trend and has an effect size index that is reported as being suitable in 
single case research data where parametric assumptions are often not met (Tate et al., 2015). It 
is unlikely that due to the small sample, parametric assumptions would be met in this study and 
thus this is the most likely statistical test of choice. Similarly, as data are unlikely to be normally 
distributed the non-parametric Wilcoxon signed-rank test will be used to compare participant 
scores on outcome measures pre and post the intervention. Data on recruitment and retention 
rates will also be reported as will data from the Participant Treatment and Acceptability 
Questionnaire. 
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Updated & Expanded Data Analysis  
Data will be presented graphically for visual analysis across and within phases, using the SCDA 
plug in for R Commander (Bulte & Onghena, 2008). Each participant will have a total of 3 
graphs, with the first focusing on ‘sleep efficiency’, measured as a percentage, the second will 
illustrate ‘sleep onset latency’, measured in minutes and lastly, the third graph will display 
‘sleep duration’, also measured in minutes. On all 3 graphs, ‘number of days’ will be on the 
horizontal axis. Additionally, the point in which the intervention started and ended will be 
illustrated on the graph by vertical lines. The following parameters will be considered when 
visually interpreting each graph: central location, trend, and variability (Morley, 2018). Central 
location involves calculating either the mean (or median values - if not normally distributed) 
of the baseline and intervention phases and then drawing a horizontal line on the graph to 
illustrate where the mean lies. Differences in mean values will then be calculated. A trend refers 
to the pattern of data points. Nugent (2001) suggests drawing a straight line from the first and 
last data points in both the baseline and intervention phases with these lines then being visually 
inspected for trends. If visual inspection indicates the presence of data trends, then Kendall’s 
Tau-b analyses will be carried out to determine whether these trends are significant. Finally, 
variation of data will be inspected. The greater the variation the less likely significant trends 
will be found, and overall conclusions made about the efficacy of the BBTI. Range lines will 
be included in the graph to illustrate variability.  
 
Partially following the parameters set out in the feasibility study by Zouharova and Gardani (in 
preparation), significant change would be indicated if two of the following were met: (1) PSQI 
score of <8, (2) SCI score of ≥24 and (3) Sleep Effiency≥85% (4) Sleep Onset Latency<20mins 
and (5) Sleep Duration ≥7 hours. Numbers (4) and (5) were not included in the feasibility study 
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and subsequently these parameter guidelines were taken from Zhu et al (2019). Inter-rater 
agreement will be sought regarding visual inspection.  
 
A large table illustrating sleep diary data for baseline and intervention phases, for all 6 
participants, will be included in the results section. A table comprising of pre and post 
intervention scores for SCI, PSQI, GAD-7, PHQ-9 will be included also.  
 
Justification of sample size 
Other than the feasibility study currently under review by Zouharova and Gardani (under 
preparation), which employed a case series design, no other study to the author’s knowledge 
has been carried out in this area. Krasny-Pacini and Evans (2018) suggest SCED designs 
typically involve a ‘small number of participants, usually one to three. Dallery, Cassidy and 
Raiff (2013) state that the number of participants in a SCED study is ‘always more than 1, 
usually around 6 but sometimes as many as 20’. As there is no clear guidance on participant 
numbers in the literature, based on the numbers by Zouharova and Gardani (under preparation), 
this study will aim to recruit 6 participants.  
 
Settings and Equipment 
The intervention will take place either in charity premises or at the participant’s own home. 
Participants will receive BBTI specific workbooks and will complete several standardised 
outcome measures pre and post intervention. 
 
50 
 
Researcher Safety Issues 
Due to the potential incorporation of home visits into the study, the researcher will follow local 
NHS lone working policy guidelines (GG&C Lone working policy, 2014). It states that the 
researcher must advise another staff member of their whereabouts, devising a ‘clock in and 
clock out’ system whereby their location is always accounted for.  
 
Critical Appraisal of Planned Methods  
Inclusion/Exclusion Criteria 
BBTI, which was tailored to meet the needs of the stroke population, may have greater validity 
if only participants experiencing their first episode of insomnia were recruited to the study - 
excluding those with a history of insomnia prior to stroke. Post stroke insomnia and non-stroke 
related insomnia could respond differently to BBTI however as the inclusion/exclusion criteria 
stands, this would not have been controlled for. Furthermore, asking participants if they had 
changed or taken any new sleep medication throughout the intervention would have been 
beneficial. Ethically, it would not be appropriate to ask a participant to withhold new 
medication during BBTI however having this information would be helpful when making 
overall conclusions about the efficacy of the BBTI intervention. Additionally, excluding all 
aphasic individuals may have been unfair and unnecessary. If individuals who were aphasic 
wished to participate and were able to communicate their sleep experiences reliably, then 
potentially another individual could complete daily sleep diaries on the participant’s behalf. 
Given that around a third of people who have a stroke experience aphasia (Flowers et al., 2016), 
excluding these individuals means that the efficacy of BBTI for post stroke insomnia would 
not be validated on a representative sample  of the stroke community.  
51 
 
Design 
Morley (2018) states that ‘measurements in the baseline are taken until a pattern emerges’ and 
‘at least 3 measurements are required to constitute a pattern’. The smallest baseline phase in 
this study was 5 days, which may have been too short to observe a sleep pattern in all cases 
and subsequently draw reliable pre and post intervention conclusions. An alternative might 
have been to provisionally set baseline phases but with the understanding that baselines may 
need to be increased if a stable pattern had not emerged in this time frame. Additionally, the 
large number of outcome measures for completion pre and post intervention, may have been 
overwhelming and off putting for participants. As the SCI and PSQI are both validated 
measures and essentially measure the same sleep characteristics, it may have been sufficient to 
include only one of these. As the PSQI specifically asks a question on pain levels, I would have 
favoured this measure over the SCI since pain is considered in the inclusion/exclusion criteria. 
 
 
Ethical Issues  
Permission will be sought from NHS ethics boards. Information and consent forms will be 
given to participants outlining the aims of the study (BPS, 2010). Confidentiality will be 
maintained by storing participant personal information securely in a locked case within a 
locked filing cabinet at NHS premises or on a password protected/encrypted file on an NHS 
computer (Data Protection Act, 2018). Personal data will be removed from research data and 
stored in a password protected Excel spreadsheet on a password protected NHS computer. Data 
will be stored securely for ten years following completion of the study in line with university 
and EU/UK guidelines (Medical Research Council, 2000). 
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Participants will be reminded throughout the information and consent processes and during the 
intervention that participation is entirely voluntary, they are free to stop or take a break at any 
point, without any impact on their overall care. 
 
Practical Applications 
Given the high prevalence of insomnia within this population, if successful, BBTI could 
potentially help many individuals achieve better sleep. Additionally, as insomnia is a risk factor 
for other conditions e.g. future stroke, positive outcomes from the BBTI may help participants 
maintain better health in future.  
If the BBTI is found to reduce participants’ symptoms of insomnia, a larger study could be 
rolled out incorporating higher participant numbers.  
 
Dissemination 
The results of the study will be written in the trainee clinical psychologist’s thesis and 
distributed to NHS Stroke Psychology Outpatient Services and to Headway charity. 
Additionally, outcomes will be disseminated via DClinPsy doctorial theses, publications in 
peer-reviewed journals and national conference proceedings.  
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Timetable   
Task Estimated Time to 
Complete 
Estimated Start Date Estimated 
Completion Date 
MRP Draft 4 months September 2017 January 2018 
MRP proposal 6 months January 2018 June 2018 
Finalise Proposal 
and Materials 
18 months June 2018 January 2020 
Ethics Submission 1 month February 2020 February 2020 
Recruit and gather 
data 
3 months March 2020 May 2020 
Data Analysis 2 weeks May 2020 May 2020 
Final write up 2 months June 2020 July 2020 
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Plain English Summary 
Introduction: Loneliness and symptoms of insomnia are higher in undergraduate students 
compared to the general population (Beutel et al., 2017). There may be a number of reasons 
for this including leaving home for the first time and a change in sleep routine (Taylor et al., 
2013).  There has been some research to suggest that insomnia and loneliness are linked and 
that as one difficulty increases/decreases then so does the other. Additionally, it has been 
suggested that the link between insomnia and loneliness may only exist when symptoms of 
anxiety and depression are also present (Choueiry et al., 2016). 
.  
Aim of the Study: 1) To explore the frequency of loneliness, insomnia, anxiety, and 
depression in undergraduate students 2) To determine if insomnia and loneliness are 
connected and if the severity of one changes with the severity of the other 3) To explore 
whether symptoms of anxiety and or depression effect the connection between insomnia and 
loneliness. 
 
Research Questions to be addressed: Is loneliness connected with insomnia in undergraduate 
students and if so, do symptoms of anxiety and depression explain this connection. 
 
Methods 
Participants: 1117 undergraduate students across 6 UK universities took part in the study. 
 
Recruitment: Undergraduates were invited to take part in the study through University emails 
and through advertisements on social media. 
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Design: Undergraduates completed an online questionnaire exploring the frequency of mental 
health problems. 
 
Key ethical issues: Completion of the questionnaire may have brought up some difficult 
feelings for participants. Advice on what to do in this situation was provided at the beginning 
and end of the questionnaire e.g. speak with your GP if you feel your symptoms are causing 
you difficulty, as well as contact numbers for the Samaritans and Breathing Space.  
 
Impact: Understanding the link between loneliness and insomnia and also whether anxiety or 
depression influences this connection, may help determine ways to manage these symptoms 
in future.  
 
References: 
Beutel, M. E., Klein, E. M., Brähler, E., Reiner, I., Jünger, C., Michal, M., ... & Tibubos, A. N. 
(2017). Loneliness in the general population: prevalence, determinants and relations to 
mental health. BMC psychiatry, 17(1), 1-7. 
Choueiry, N., Salamoun, T., Jabbour, H., El Osta, N., Hajj, A., & Rabbaa Khabbaz, L. (2016). 
Insomnia and Relationship with Anxiety in University Students: A Cross-Sectional 
Designed Study. PloS one, 11(2), e0149643. 
https://doi.org/10.1371/journal.pone.0149643 
 
Taylor, D. J., Bramoweth, A. D., Grieser, E. A., Tatum, J. I., & Roane, B. M. (2013). 
Epidemiology of insomnia in college students: relationship with mental health, quality 
of life, and substance use difficulties. Behavior therapy, 44(3), 339-348. 
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Abstract 
 
Background: Previous research has found an association between loneliness and insomnia 
however it is unclear if this link exists within a student population and if so, whether it is 
mediated by feelings of anxiety and depression. This study explores this further. 
Methods: Secondary data was analysed on 1117 undergraduate students, across 6 UK 
Universities, who had completed self-report measures of insomnia, loneliness, anxiety, and 
depression 
Results: A moderate association (r=-.388, p<.001) was found between loneliness and insomnia. 
Multiple regression indicated that depression fully mediated the relationship between 
loneliness and insomnia, whilst there was no mediating effect of anxiety.  
Conclusion: Students with symptoms of insomnia and loneliness are likely to experience 
symptoms of depression although not necessarily anxiety. Although loneliness is not classed 
as a psychiatric disorder, treating symptoms of depression may benefit those with complaints 
of loneliness and insomnia since a reduction in depression may indirectly reduce these 
symptoms too. 
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Introduction 
Symptoms of insomnia within the student population are estimated to range between 8% and 
69%, depending on the insomnia criteria used (Taylor et al., 2013). Poor sleep, frequent 
awakenings and low total sleep time are common sleep complaints reported by students 
(Bulbotz et al., 2001). Multiple factors may account for a higher prevalence of insomnia within 
this population, including academic pressure, a change in bedtime routine and easy access to 
drugs and alcohol (Taylor., 2013).  
Undergraduates report loneliness and this can be associated with having few established social 
connections whilst transitioning to University, often in the context of leaving home for the first 
time (Hom et al, 2017). Diehl et al (2018) found that 32% of undergraduates experienced 
loneliness, compared to 10% found within the general population (Beutel et al, 2017).  
Although limited, recent evidence suggests that insomnia (Hom et al., 2017), lower sleep 
efficiency (Cacioppo et al., 2002), poorer sleep quality (Harris et al., 2013) and increased sleep 
fragmentation (Kurina et al., 2011) are associated with loneliness. Cacioppo & Cacioppo 
(2014) hypothesise that this link may be due to the evolutionary fight or flight response and 
that loneliness signifies a social disconnect and an unsafe environment, leading to 
hypervigilance for social threats.  
Symptoms of insomnia significantly correlate with other psychiatric disorders common within 
the student population including anxiety (Choueiry et al., 2016) and depression (Akram et al., 
2019). The relationship between loneliness and insomnia has been found to be mediated by 
anxiety (Zawadzki, Graham & Gerin, 2012), and by depression but not anxiety (Hom et al., 
2017). Therefore, although there is evidence for an association between loneliness and 
insomnia, the mediating role of anxiety and depression is unclear. The present study explores 
this further. 
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Research Questions 
1) Is loneliness associated with insomnia in undergraduate students?  
2) Does anxiety and/or depression mediate any relationship between loneliness and 
insomnia? 
 
2. Methods 
2.1 Sample and Procedure 
 
Data from an earlier study was used (Akram et al (2020a, b, c) with Dr Gardani a supervisor 
of this project and a co-author of the previous study, granting access to the dataset (Appendix 
3.1). This study explored the prevalence of mental health difficulties in students and was 
approved by Sheffield Hallam University Research Ethics Committee (Reference Number: 
ER7368595). Undergraduate students across 6 UK universities were recruited via institutional 
course participation schemes and social media pages. A course credit was provided to students 
on request at completion if they were eligible. Participants completed an online questionnaire, 
designed to measure the prevalence of psychiatric symptoms including depression, loneliness, 
anxiety, and insomnia and although not analysed in this report, questions also on mania, 
psychosis, perfectionism, and suicidal ideation. After removing incomplete responses (377), 
data from 1117 individuals were included in the final analysis.  
 
2.2 Measures 
Loneliness was assessed using the UCLA Loneliness Scale (Russell, 1996). The UCLALS has 
20-items that assess how often an individual feels disconnected from others. Items are scored 
using a 4-point scale (1=never - 4=always). Scores on the UCLALS range from 20-80, with 
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higher scores indicating greater loneliness. The UCLALS is not a clinical tool and no clinical 
‘cut-offs’ have been developed. 
Symptoms of depression were measured using the Patient Health Questionnaire: (PHQ-9; 
Lowe et al., 2004), a nine-item measure assessing key symptoms of depression as outlined in 
the DSM-5. Items are scored on a 4-point scale. The maximum score on the PHQ-9 is 27, with 
higher scores indicating greater severity of depression. A score of 10 or more indicates possible 
depression.  
Anxiety was measured using the Generalised Anxiety Disorder-7: (GAD-7; Shear et al., 2006).  
Seven items are scored on a 4-point Likert type scale (0=not at all - 3=nearly all days), 
providing a total score ranging from 0-28. Higher scores indicate higher levels of anxiety, with 
scores ≥11 indicating possible cases of generalised anxiety disorder.  
Symptoms of insomnia were assessed using the Sleep Condition Indicator (SCI; Espie et al., 
2014), an eight-item questionnaire with items scored on a 5-point scale; total scores range from 
0-32, and higher scores indicate better sleep.  
 
2.3 Statistical Analysis 
All analyses were carried out using IBM SPSS, Version 24.0 (IBM Corp, Armonk, N.Y., USA). 
Missing data and outliers were checked for via frequency tables and boxplots. A data point was 
defined as an outlier if it was more than 1.5 interquartile ranges below the first quartile or above 
the third quartile and located out with the whiskers of the boxplot. All data were present, and 
no outliers were identified.  
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A Shapiro-Wilk’s test (Shapiro & Wilk, 1965) and a visual inspection of histograms and 
boxplots showed that scores for loneliness were normally distributed, and scores for anxiety, 
depression and insomnia were not normally distributed (p<.05).  
As not all data were normally distributed, Spearman’s correlations were carried out between 
insomnia symptoms, loneliness as well as anxiety and depression.  
A linear regression was performed, with loneliness as the independent variable and insomnia 
as the dependent variable to determine if loneliness predicted insomnia. A multiple regression 
was then performed, comprising of loneliness and both mediators (anxiety and depression) as 
independent variables to determine whether they significantly predicted insomnia. Regression 
indicated that the four conditions of mediation set out by Baron & Kenny (1986) were met 
(Appendix 3.1), allowing the strength of mediation to be calculated using PROCESS macro 
Version 3 (Hayes, 2012). Significance was set at the p<0.05 level (two-tailed). 
 
2.4 Results 
Of the 1117 undergraduates in the analysis, 83% were female. The mean age was 20, with an 
age range of 18–56 years. Overall, 43% scored below ≤16 on the SCI, indicating ‘probable 
insomnia’ whilst 46% and 43% scored in the ‘moderate to severe’ range for depression and 
anxiety, respectively. Mean score on the UCLALD was 44.7 (Table 1). 
 
Table 1. Median (IQR) and Mean (SD) of scores for outcome measures  
Outcome measure 
(clinical cut off 
scores) 
Median or 
Mean* Score 
Proportion 
scoring above   
clinical ‘cut-
off’; % and (N) 
Interquartile 
Range (range) 
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PHQ–9 (≥10) 9 46% (509) 4-15 (0-27) 
GAD–7 (≥10) 8 43% (478) 4-14 (0-21) 
SCI (≤16) 18 43% (478) 12-24 (0-32) 
UCLALD 44.7* (12.3) N/A 35-54 (20-76) 
 
Insomnia was significantly correlated with loneliness (r=-.381, p<.001), anxiety (r=-.519, 
p<.001) and depression (r=-.635, p<.001).  Significant associations were also found for 
loneliness with anxiety (r=.573, p<.001), and depression (r=.650, p<.001) and between anxiety 
and depression (r=.784, p<.001).  
 
Linear Regression 
A linear regression with loneliness as the predictor and insomnia as the outcome variable was 
significant, β=-0.376, SE=.016, p<.001 (one of four requirements of mediation, Baron & 
Kenny, 1986). 
 
Multiple Regression 
Self-report of insomnia was the dependent variable and ratings for loneliness, anxiety and 
depression were independent variables. Preliminary analysis indicated that assumptions 
regarding linearity, multicollinearity and normality were met. The model for insomnia was 
significant (R²=.39); scores on the SCI were predicted by depression (Beta=-.618, p=.001) but 
not loneliness (Beta=-.064, p=.066) or anxiety (Beta=.065, p=.082),  (see Table 2). 
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Table 2: Regression model of predictors of insomnia, with confidence intervals reported in 
brackets.  
 B (95% CI) SE B Beta p value 
Constant 29.448 
(25.42, 32.22) 
1.151  .001 
Loneliness -.038 
(-.006, .065) 
.018 -.064 .066 
Anxiety -.078 
(-.172, .005) 
.045 -.065 .082 
Depression -.674 
(-.766, -.591) 
.044 -.618 .001 
R ² = .39  
 
Mediation analysis 
Mediation analysis indicated a significant indirect effect of loneliness on insomnia via 
depression and no significant indirect effect of anxiety was found (Figure 1). 
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Figure 1: Model of loneliness as a predictor of insomnia, potentially mediated by anxiety and 
depression. Regression co-efficients and significance levels are provided.  
 
 
 
Depression 
Loneliness Insomnia 
 
Anxiety 
Direct effect, b=0.03, p=0.10 
 
Indirect total effect (through both anxiety and depression), b=-0.27, 95% CI [-0.30, -0.24]  
Indirect total effect (through anxiety), b=-0.02, 95% CI [-0.05, 0.00]   
Indirect total effect (through depression), b=-0.24, 95% CI [-0.28, -0.21]   
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Discussion 
This study found a significant association between loneliness and insomnia in undergraduates 
with a large effect. When depression was added to the model, the direct effect of loneliness on 
insomnia was no longer significant, suggesting that the relationship between loneliness and 
insomnia is best understood through depression. Females scored significantly higher on 
measures of insomnia, anxiety, and depression but no significant differences were found for 
loneliness. No significant mediating effect of anxiety was identified. 
Just under half (43%) of students scored in the ‘probable’ range for insomnia, in the middle of 
the range (9-69%) reported by Taylor et al (2003). The prevalence of depression (46%) was 
higher than previous findings in students e.g. 33-35% (Beiter et al 2015; Jenkins et al 2020), 
whilst complaints of anxiety (43%) were similar to previous findings (Taylor et al., 2003; 
Beiter et al 2015). There was a high proportion of females in this study and this could account 
for the high rates of depression found. Females in the general population tend to self-report 
higher rates of depression (Bramness et al, 2010). Furthermore, there is a possible selection 
bias, whereby the study may have been more attractive to individuals experiencing sleep 
problems which is also a symptom of depression (Zimmerman et al., 2015). Lastly, this study 
included a large sample and recruited students from differing faculties, across multiple 
Universities. The inclusion of a potentially more diverse range of participants in this study 
could explain why results are out with the previously reported trend.  
Hom et al (2017) reported findings that are similar to those in the present study (a relationship 
between loneliness and insomnia that was mediated by depression and not anxiety).  
On the other hand, Cacioppo et al (2002) found loneliness predicted insomnia in a population 
of students, even when depression was controlled for. The sample size was small (N=37) and 
two-thirds (24) were male. Participation in this study was dependent on individuals scoring in 
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the ‘non-clinical’ range of the Beck Depression Inventory (BDI), a self-report measure. As 
males have been found to under report symptoms of depression on self-report measures 
(Sigmon et al., 2005), it is possible that depression was under-reported in the study by Cacioppo 
et al (2012) given the high proportion of males. If so, depression may not have been controlled 
for as intended. 
In relation to loneliness, a growing body of research indicates that social networks and 
connections significantly impact mental wellbeing (Jetten, Haslam & Haslam, 2012) and 
subsequently evidence-based treatment options to reduce perceived loneliness have been 
developed (Cacioppo et al, 2015). These include programs that a) increase social skills b) 
increase social contacts and c) address maladaptive social cognitions e.g. Cognitive 
Behavioural Therapy which the meta-analysis by Masi et al (2011) found to be most effective 
of all. Although to the author’s knowledge no studies exploring the efficacy of interventions 
targeted at loneliness have taken place specifically in the undergraduate student population, the 
positive findings within the general adult population are encouraging and possibly 
generalizable to students, since there is a crossover of age between these two groups (Masi et 
al, 2011). Additionally, the high association of loneliness with anxiety and depression in this 
study suggest that it may share similar constructs to these variables and subsequently treating 
these disorders could indirectly reduce perceived loneliness also.  
Study Limitations & Future Research 
Inconsistencies between self-report measures and objective measures of sleep e.g. 
polysomnography have been identified (Morin, Cuthbert & Schwartz, 1994). As this study 
utilised subjective measures only, there is room for more comprehensive assessment of 
insomnia in future. Discrepancies in modes of measurement mean that insomnia severity could 
have been under or over-estimated, which could affect the validity of overall findings.  
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The significant mediating effect of depression on loneliness and insomnia is perhaps 
unsurprising given that insomnia is a symptom of depression. One way to explore and 
potentially minimise this immediate ‘head start’ in mediation would be to complete mediation 
analysis incorporating all of the questions on the PHQ-9 measure in the first instance before 
going on to complete a second mediation analysis but this time removing the outcomes of the 
sleep related question on the PHQ-9 measure. This would offer insight as to whether depression 
mediates the loneliness and insomnia relationship solely because of its shared constructs with 
sleep or whether its mediating effects are present beyond this.  
There was an over-representation of females in this study and gender differences in the 
regression and mediation models were neither explored nor controlled for as this was out with 
the scope of the report. Subsequently results obtained may not be representative of the wider 
population. Similarly, age was not explored or controlled for during data analysis. Although 
95% of the sample in this study were aged between 18 - 25 years, mature students were not 
excluded and could have influenced overall results obtained. Future studies should aspire to 
explore gender and age differences and whether they impacted outcomes. Finally, longitudinal 
studies that include time frames pre and post University, e.g. at school and post University 
employment, may capture causality and identify predictor and moderating variables. 
Longitudinal studies exploring these variables have been carried out in differing populations 
e.g. Santini et al (2020) found loneliness and social isolation predicted anxiety and depression 
in a sample of older adults however due to population trait differences these findings may not 
be generalizable to undergraduate students. 
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Conclusion 
Loneliness was associated with insomnia in University undergraduates however this 
relationship was driven solely by symptoms of depression. This effect may be associated with 
gender, with a high proportion of females included in the study and with females reporting 
more depression, as was the case in this study. The results found suggest that a direct 
relationship between loneliness and insomnia may not exist but instead is best understood 
through their mutual association with depression. 
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authors of a paper and to all categories of submissions. Papers that do not include a Disclosure 
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For abbreviations of journal names, refer to “List of Journals Indexed in Index Medicus.” 
Manuscript Format Requirements 
Manuscript should be provided in Microsoft Word. 
Pages should be numbered. 
Lines should be double spaced. 
Do not number the lines. 
Manuscripts should be structured using the following components: 
Title Page (Page 1 of manuscript) 
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The Statement of Significance is limited to 120 words and must follow the abstract. 
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methods, abbreviations, or acronyms, unless necessary. 
Introduction 
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Methods 
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Results 
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Preprint Repositories 
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used to join the first and last numbers of a series. 
• Commas should be used without spaces to separate other parts of a multiple-reference 
citation. 
Sample citations within the body of a paper 
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• The patients were studied as follows3,4 
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guidelines for the manuscript, tables, figures and supplementary material. Once the files are approved 
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Statements and opinions expressed in the articles and communications herein are those of the 
author(s) and not necessarily those of the editors, the publisher, or the Sleep Research Society (SRS), 
and the editors, the publisher, and SRS disclaim any responsibility or liability for such materials. The 
editors, the publisher, and SRS do not guarantee, warrant, or endorse any product or service 
advertised in this publication, nor do they guarantee any claim made by the manufacturer of such 
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Appendix 1.2 – Search Strategy 
 
Author title, abstract and keyword search terms (used across all databases)  
 
Cognitive behavioural therapy terms: (cognitive within three words of (treat OR therapy) 
OR cognitive behav* therapy OR cognitive behave* treat* OR behav* therapy OR cognitive 
therapy OR CBTI 
 
Insomnia terms: (insomnia OR insomni* OR chronic insomnia OR sleep OR sleep prob*)  
 
Old age terms: (old* within 3 words of adult OR person OR people OR woman OR man OR 
male OR female) OR late life OR elderly OR ageing 
 
(* denotes the truncation command where the search will identify all words beginning with that 
term) 
 
Separate databases were searched using the same terms, matched to the database 
thesaurus. The final search combining insomnia, CBT and old age terms were combined 
using the Boolean operator AND. 
 
94 
 
Appendix 1.3 - Data Extraction Tool 
     Data Extraction Tool 
Study Title:  
Study Authors:  
Study Design:  
Sample Size: 
How was the sample obtained?  
Sample characteristics (including age, gender ratio) 
Groups similar at pre-test or adjustments  
Interventions used (Specific CBT components):  
Who delivered the treatment intervention (their training/qualifications)  
Sleep medication use?  
Description of Intervention/Protocol (how many groups, was the treatment protocol 
manualised?) 
Randomisation Process:  
Specific outcomes used to measure levels of Insomnia: 
Specific outcomes of insomnia measured:  
Information on rater blinding to treatment allocation?  
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Intention to treat analysis offered/handling of drop outs described, if attrition rate 
exceeds 15% 
Statistical Analysis used?  
Effect sizes documented?  
 
Any additional details: 
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Appendix 1.4 Quality Rating Scale 
 
Quality Rating Scale 
(Adapted from the Clinical Trials Assessment Measure, Tarrier & Wykes 2004) 
 
Reviewer:  
Title:  
Authors:  
Date:  
Journal:  
 
Sample (Maximum score = 15) 
 
1. Is the sample a convenience sample (score 2) or a geographic cohort (score 5) or highly 
selective sample e.g. volunteers (score 0) (Convenience sample: e.g. clinic attendees, 
referred patient., geographic cohort: all eligible individuals in a given area). 
 
 
2. Is the sample size greater than 27 participants per group (score 5) or based on adequate 
and described power calculations (score 5). If no to both questions, then score 0. 
 
 
3. Is data provided on the characteristics of refusers/drop out? Yes (score 5) No (score 0). 
 
 
Total:  /15 
 
Control groups (maximum score = 26) 
 
1. Is there a control group? Yes (score 5) 
 
 
2. Is the control group TAU (score 6) and/ or a control group that controls for non-specific 
effects or other established or credible treatment (score 10). 
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3. Groups similar at pre-test? Or adjustments made? (score 5) 
 
 
Total:  /26 
 
Allocation (maximum score = 16, if no control group – score 0 for section) 
 
1. Is there true random allocation or minimisation allocation to treatment groups (if yes 
score 10) 
 
 
2. Is the process of randomisation described (score 3) 
 
 
3. Is the process of randomisation carried out independently from the trial research team 
(score 3) 
 
 
Total:  /16 
 
 
Outcome assessment (maximum score = 39) 
 
1. Are the assessments carried out by independent assessors and not therapists (score 10) 
 
 
 
2. Were standardised outcome measures used to assess outcomes  (yes - score 5/partically 
score 3) or were participant perspectives of symptoms used only (score 3 if only the 
latter) 
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3. Were the outcome measures of insomnia used valid and reliable? (Yes score 5, no score 
0) 
 
 
4. Was there a long term follow up measurement of at least 6 months duration of insomnia, 
post treatment completion (if yes score 3) 
 
 
5. Are assessments carried out blind (masked) to treatment group allocation (score 10) 
 
 
6. Are the methods of rater blinding adequately described (score 3) 
 
 
7. Is rater blinding verified (score 3) 
 
 
 
Total: /39 
 
 
Analysis (maximum score = 20) 
 
1. The analysis is appropriate to the design and type of outcome measure (score 5) 
 
 
2. The analysis includes all those participants as randomised (sometimes referred to as an 
intention to treat analysis) (score 6) and an adequate investigation and handling of drop 
outs from assessment if the attrition rate exceeds 15% (score 4) 
 
3. Was an effect size calculation completed (score 5) and if not was there sufficient 
information provided for effect sizes to be completed by the reader (score 3) 
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Total: /20 
 
CBT for insomnia (maximum score = 31) (complete) 
 
1. Was the CBTI intervention adequately described to allow replication? (score 5) 
 
 
2. Were the CBT components used appropriate and in line with the evidence base for 
CBTI (score 5) 
 
 
3.  Was a treatment protocol or manual used to allow for consistency of treatment delivery 
(score 5) 
 
 
4. Was information provided on the training of therapists (score 3) were therapists 
adequately trained to deliver CBT (if yes to both score 5) 
 
 
5. Was adherence to treatment protocol assessed (score 5) 
 
 
6. Was subject retention for the CBT intervention 85% or higher (score 3) 
 
 
7. Were recommendations provided for improving the intervention? (score 3) 
 
 
 
Total: /31 
Total Score for Paper: 
Calculated as percentage:   
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Appendix 1.5 Breakdown of CTAM quality rating scores for each included study 
 
Paper Sample 
(Maximum 
score = 15) 
Control 
groups 
(maximum 
score = 26) 
 
Allocation 
(maximum 
score = 16) 
Outcome 
assessment 
(maximum 
score = 39) 
 
Analysis 
(maximum 
score = 20) 
 
CBT for 
insomnia 
(maximum 
score = 31) 
 
Total score for 
paper 
(maximum = 
147) 
Quality Rating 
 
49% or less = Low 
50-74% = Medium 
75% or more = High 
Inter-rater 
concordance, 
for double 
rated studies  
1. McCrae 
et al (2018) 
15  20 10 30 20/20 21 116 
= 79% 
High   
2. Alessi et 
al (2016) 
12 20 16 23 20 21 112 
= 76% 
High   
3. Irwin et 
al (2014) 
10 20 16 23 18 23 110 
= 76% 
High  96% 
4. Martin et 
al (2017) 
7 20 10 20 18 26 101 
= 69% 
Medium  97% 
5. Tanaka et 
al (2019) 
12 26 16 5 14 19 92 
=63% 
Medium   
6. Sadler et 
al (2018) 
2 20 16 8 14 31 91 
= 62% 
Medium   
7. Dolu et al 
(2018) 
7 26 0 10 14 11 68 
=46% 
Low  96% 
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Appendix 1.6 Practice Points & Research Agenda 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Practice Points 
 
• Insomnia is common within the older adult 
population 
 
• Non-pharmacological treatment options for 
insomnia are not suitable for long term use 
 
 
• CBTI and its components is a safe and effective 
treatment method in reducing symptoms of 
insomnia in older adults, with effects maintained 
at follow up. 
 
• Self-reported measures of insomnia tend to 
overestimate treatment effects compared to 
objective outcomes 
 
 
Research Agenda 
 
• Studies investigating the efficacy of CBTI in older 
adults are lacking 
 
• Larger, high quality longitudinal studies, 
investigating the efficacy of CBTI are needed to 
assess the long-term efficacy of the intervention 
 
• Studies using both objective and subjective 
outcomes to measure treatment efficacy are 
needed to obtain a deeper understanding of why, 
when and in which sleep domains specific 
discrepancies are most likely to exist 
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Appendix 2.1 Study Flyer 
 
                                                                                                  
  Study Flyer 
 
 Brief Behavioural Intervention for Post Stroke 
Insomnia 
WHAT IS THE STUDY ABOUT?  
This study is interested in exploring the effectiveness of a brief behavioural 
intervention in people experiencing sleep problems following a stroke.  
We are looking to invite people aged 18 who have had a stroke at least 3 
months ago but less than 18 months ago and are experiencing sleep problems.  
The study would involve completing sleep diaries for approximately 6 weeks as 
well as trying out strategies aimed at improving sleep. 
Please speak to a member of Headway Staff if you would like to find out 
more about the study. 
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Appendix 2.2 Participant Information Sheet 
 
Participant information sheet (V11, 03.04.2020) 
 
Study title: The Effectiveness of a Brief Behavioural Treatment for Insomnia (BBTI), in the 
management of Post Stroke Insomnia: A pilot study 
 
    Information Sheet 
My name is Kirsty McDonald and I am undertaking a project as part of my Doctorate in 
Clinical Psychology. I invite you to take part in this study. However, before you decide 
whether to do so, I need to be sure that you fully understand why I am carrying out this study 
and what it would involve if you agreed. I am therefore providing you with the following 
information. Please read it carefully and be sure to ask any questions you may have. If you 
wish further information about the study, please don’t hesitate to contact me via the contact 
details provided.  
 
   What is the purpose of the study? 
There is a growing body of research indicating that a BBTI may be effective at reducing 
symptoms of insomnia, including difficulty falling asleep, frequent night-time wakening and 
early morning awakening, within the general population. A BBTI is a type of talking therapy 
that tends to be short-term, usually 4 sessions long and does not involve the use of 
medication. Instead the intervention tends to involve making some changes to a person’s 
daily activities and behaviours that perhaps without realising, are adding to the problem. 
There has been very little research however in evaluating whether the same intervention is 
effective for individuals who are experiencing sleep difficulties, commonly referred to as 
insomnia, after having a stroke. The aim of this study is to determine how effective a BBTI is 
in reducing symptoms of post stroke insomnia. The study is a pilot study, which means that it 
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is a small study, consisting of a small number of participants. It aims to determine whether 
the research procedure used in this study would be suitable for larger scale studies. 
 
The present study will be submitted as part of a research portfolio for a Doctorate in Clinical 
Psychology at the University of Glasgow. 
 
   Who is suitable to take part in the study? 
Individuals who are experiencing sleep related difficulties after having a stroke are invited to 
take part in the study. The stroke must have taken place at least 3 months ago but less than 18 
months, prior to your participation in the study. Participants should not have been 
experiencing insomnia within the previous 3 months leading up to the stroke. Additionally, 
individuals should not have received any cognitive behavioural therapy in the treatment of 
their post stroke insomnia. 
. 
 
   What does taking part involve? 
Taking part in this study involves attending a 60-minute initial meeting, a 60 minute long 
intervention session, three 20 minute sessions and finally a follow up meeting lasting 
approximately 45 minutes. All meetings can take place either at your own home or at a 
charity in Glasgow called Headway, which specialises in helping people with an acquired 
brain injury.  
 
The initial 60-minute meeting will involve discussing more about what the study involves, 
determining your suitability for the study and completing some questionnaires about your 
mood and current levels of sleep. It is important to gather information on your current sleep 
activity so as we can compare your sleep patterns before and after taking part in the study. 
This is called a baseline phase. The baseline phase will last for 7 days. After the completion 
of the baseline period, you will then start the study intervention which will last 4 weeks in 
105 
 
total. Throughout the 4-week intervention you will have one session with the researcher per 
week, either over the phone or at your own home. The first week’s session will last 60-
minutes and the remaining 3 sessions will last 20 minutes, Throughout the duration of the 
study you will be asked to complete a sleep diary every morning to help the researcher 
monitor your sleep/wake cycle. Once the 4 weeks have come to an end, you will then return 
to a 7-day baseline period where your sleep activity will continue to be monitored. 
 
The final meeting, lasting approximately 45 minutes in duration will take place once the 
study has ended, to obtain feedback and to repeat the questionnaires completed in the first 
meeting. 
Participants will be given a workbook to keep which includes information covered in the 
sessions to use as a reference point throughout the study and after its completion. 
 
Who is conducting the research? 
Kirsty McDonald, a Trainee Clinical Psychologist from the University of Glasgow is carrying 
out this study. It is being supervised by Dr Maria Gardani and Professor Tom McMillan also 
from the University of Glasgow, as well as Dr Eleni Pataraki, who works within the NHS. All 
data recorded from the study will be anonymised. Only those who are on your care team or in 
the research team will be able to view the data. Additionally, the sponsor of the study, NHS 
GG&C, may also need to access participants identifiable information to ensure the study is 
being carried out correctly. 
 
Do I have to take part? 
No, participation is voluntary, and it is up to you to decide. If you would like to take part, you 
will be asked to sign a consent form to show you have agreed. If you would like to take a 
break during any part of the study, you would be free to do this. You would also be free to 
withdraw from the study at any time, and you would not have to give a reason for this. 
Withdrawing from the study would not affect the standard of care you receive or your future 
treatment. 
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What happens to the information? 
Information sheets completed by participants e.g. outcome measures and sleep diaries will be 
stored in a locked briefcase, within a locked cabinet on NHS premises. Similarly participant 
information that will be stored on a computer will be fully anonymised and will be stored on 
NHS and University desktop computers, which are password secured. All data will be stored 
in accordance with the Data Protections Act as well as EU, UK, University of Glasgow and 
NHS policy for the duration of 10 years. After 10 years, the data will be destroyed.  
 
Will you contact my GP? 
With your consent, the researcher will inform your GP that you are participating in the study.  
If you would like to see an example of the letter that would be sent to your GP, please just 
ask the researcher. 
 
What are the possible negative effects on me? 
The intervention may generate a number of emotional reactions in you. These emotions may 
be positive or negative. Should you experience a negative emotional reaction you will be 
offered the opportunity to discuss this with the researcher or a member of your clinical 
support team. 
 
What are the possible benefits of taking part? 
You may experience a reduction in your symptoms of insomnia because of taking part in this 
study. Additionally, by taking part, you are helping us determine whether a brief behavioural 
intervention for insomnia is also effective for individuals experiencing insomnia post stroke. 
 
 
Who has reviewed the study? 
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This study has been reviewed and approved by an NHS Research Ethics Committee and by 
the NHS Greater Glasgow & Clyde Research and Development department.  
 
What do I do now? 
If you are interested in taking part in the study, then please either contact the researcher 
Kirsty McDonald on the email address or phone number below. Alternatively please 
complete the note of interest slip attached and send it to the researcher Kirsty McDonald, 
Trainee Clinical Psychologist, West of Scotland Cystic Fibrosis service, Level 2, Zone 3, 
Office Block, QEUH, 1345 Govan Road, Glasgow or after completion, hand the note of 
interest slip to a staff member who will contact the researcher on your behalf. The researcher 
will then contact you to arrange a suitable time to meet.  
 
If you have any further questions? 
You will be given a copy of this information sheet and signed consent form to keep. If you 
would like more information about the study please contact Kirsty McDonald, University of 
Glasgow, by email: k.mcdonald.2@research.gla.ac.uk or telephone: 0141 451 6270 or 
alternatively Dr Maria Gardani, University of Glasgow, by email: 
maria.gardani@glasgow.ac.uk or telephone: 0141 330 2000.  
 
If you wish to speak to someone not closely linked to the study, please contact Dr Hamish 
McLeod, Programme Director, Doctorate in Clinical Psychology Programme, University of 
Glasgow, Section of Psychological Medicine, email: Hamish.McLeod@glasgow.ac.uk 
, Tel no:0141 211 3922 
 
Other useful contact numbers to use should you experience any distress out with the 
study: 
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NHS 24:111 In an emergency: 999 Breathing Space:0800 83 85 87 Samaritans: 116 123 
Your own GP during working hours (9am – 5.30pm, Mon-Fri) 
 
Thank you for taking the time to read this participant information sheet and for any 
further input you may wish to have.  
 
--------------------------------------Note of Interest Slip-------------------------------------------------- 
Study title: The Effectiveness of a Brief Behavioural Intervention, in the management of 
Post Stroke Insomnia 
Please complete the following information and either send it to: Kirsty McDonald, Trainee 
Clinical Psychologist, West of Scotland Cystic Fibrosis service, Level 2, Zone 3, Office 
Block, QEUH, 1345 Govan Road, Glasgow or alternatively give this slip to your clinician 
who will contact the researcher on your behalf. Your personal information will not be used 
for purposes other than the study 
Name ____________________________ 
Address  
 
Telephone Number _________________________ 
Preferred method of contact: Letter       Telephone 
I consent to the researcher, Kirsty McDonald, contacting me about the above study  
I consent to my clinician contacting the researcher, Kirsty McDonald, on my behalf  
Signed _________________________________    Date_________________________ 
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Appendix 2.3 Consent Form 
 
 
Participant Consent Form 
Researcher contact details: 
Kirsty McDonald, University of Glasgow, by email: k.mcdonald.2@research.gla.ac.uk. Telephone: 
0141 314 6969 
Dr Maria Gardani, University of Glasgow, by email: maria.gardani@glasgow.ac.uk. Telephone:   
0141 330 2000 
 
Participant ID Number:      
Date:  
     
Title: A brief behavioural intervention for post stroke 
insomnia.         
                                                                                                              
     Please place your initials in the boxes below  
1. I confirm that I have read the participant information sheet dated 03.04.2020 (V11)  
for the above study. I have had the opportunity to consider the information,        
ask questions and have had these answered satisfactorily.  
                                                              
2. I understand that my participation is voluntary and that I am free to withdraw         
at any time without giving any reason, without my medical care being affected.  
  
3. I am happy for you to advise my GP of my participation in the study  
  
4. I agree that my medical record can be accessed by the researcher,  
solely to obtain further information on my stroke.  
 
 
5. I understand that data collected during the study may be looked  
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at by those individuals who form the research team for the study 
(the research team is outlined in the information sheet) as well as  
representatives of the study Sponsor, NHS GG&C, for audit purposes.  
 
   
6. I agree to take part in the above study.  
  
 
 Name of Participant  Date        Signature  
 
                     
     
 Name of Researcher  Date        Signature  
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Appendix 2.4 Outcome measures and their psychometric properties for completion in the 
study 
 
PSQI 
The PSQI (Buysse et al, 1989) will be completed pre and post the intervention to monitor 
whether there has been a change in perceived quality of sleep. A score of 5 or higher 
indicates poorer sleep. The PSQI has been found to have high test-retest validity and 
reliability (Buysse et al, 1989). 
SCI 
The SCI (Espie et al, 2014) will be completed by participants pre and post intervention. The 
SCI is an 8-item questionnaire, with a higher total score indicating better sleep. The SCI has 
been shown to be internally consistent, sensitive to change and with high correlation to other 
sleep screening tools e.g. PSQI (Espie et al, 2014). 
The Patient Health Questionnaire (PSQ-9)  
 The PHQ-9 (Kroenke & Spitzer, 2001) is a 9-item self-report questionnaire, based on how 
individuals have been feeling over the past two weeks.  Evidence supports reliability and 
validity of the PHQ-9 as a measure of depression in people with physical health difficulties 
(Kroenke & Spitzer, 2001).  
The Generalised Anxiety Disorder (GAD-7) 
The GAD-7 (Spitzer et al, 2006) is a 7 item self-reported anxiety questionnaire. Evidence 
supports the GAD-7 as a measure of anxiety in people with mental health difficulties, with it 
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demonstrating high internal consistency, good validity and sensitivity to change (Shear et al, 
2006). 
Mini Montreal Cognitive Assessment (MMoCA) 
The mini-MOCA is a brief screening tool designed to detect mild forms of cognitive 
impairment, with a total score of 7 or lower out of 10, indicating cognitive impairment. The 
mini-MoCA, is a shorter version of the longer Montreal Cognitive Assessment (MOCA; 
Nasreddine et al, 2005) screening tool, requiring less time for completion. Mai et al (2013) 
found participant scores on the mini-MoCA to be highly correlated with the scores obtained 
on the full version. The mini-MoCA is available to use free of charge and has a completion 
time of approximately 5 minutes. 
 
References 
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Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and 
practice. Psychiatry Research 28:193-213. 
 
 
Kroenke, K.,& Spitzer, R.L. (2001). The PHQ-9: validity of a brief depression severity measure. 
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 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 
1. What time did you wake up this 
morning? 
       
2. What time did you get out of bed 
this morning? 
       
3. What time did you go to bed at 
last night? 
       
4. What time did you put the light 
out last night or attempt to go to 
sleep at? 
       
5. How long did it take you to fall 
asleep? 
       
6. How many times did you wake in 
the night? 
       
7. How long were you awake during 
the night? 
       
8. How long did you sleep for 
altogether? 
       
9. How much alcohol did you have 
last night? 
       
10. Did you take any medication last 
night? 
       
Appendix 2.5 Participant Sleep Diary      
Sleep Diary 
Week Beginning:  
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(for the last 2 questions please answer using the following scale: 0 = not at all, 1 = slightly, 2 = moderately, 3 = quite a lot, 4 = very 
11. How well rested do you feel 
this morning? 
       
12. Was your sleep of good quality?        
Espie (2012) 
Reference 
Espie, C. (2012). Overcoming insomnia and sleep problems: A self-help guide using cognitive behavioural techniques. Robinson
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Appendix 2.6 Session by session account of the BBTI based on the protocol by Troxel et al 
(2012). 
Session 1: 
The first BBTI session will be a one to one, 1 hour long, face to face intervention. This 
session will offer background information on sleep including the mechanisms of sleep as well 
as healthy sleep behaviours in line with sleep hygiene recommendations. A workbook 
exploring ‘good’ and ‘bad’ sleep habits is then provided to the participant with discussion 
around this taking place. This workbook is also used as a way of guiding discussion toward 
processes that control sleep. A personalised sleep schedule will be adapted for each 
participant, indicating their recommended bed and wake up time, activities to do before bed 
etc. A general rule for time in bed will be (sleep time + 30 mins, but not < 6 hr). 
Session 2 (1 week after session 1): 
A 20-minute, face to face meeting at the participant’s home, or via telephone. Discussion 
takes place around how the participant has been finding completing the sleep diary and how 
their sleep and functioning has been over the past week. Additional general questions are 
asked about functioning and levels of sleepiness. How well a patient has been able to adhere 
to the pre-determined sleep schedule will be asked, problem solving any difficulties that may 
have arisen in achieving this. 
Session 3 (1 week after session 2): 
A 20-minute, face to face meeting at the patient’s home, or via telephone. Review progress 
and adherence to the protocol, problem solve difficulties and where appropriate, make 
changes to the sleep schedule. Sleep diaries will indicate the participant’s sleep onset latency 
and wake time after sleep onset. Depending on these levels, adjustments can be made to total 
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sleep time as well as total time spent in bed. With the new sleep schedule being followed for 
the next week. Motivational reinforcement will also be offered reminding patients that initial 
behavioural change is difficult but with time this will become easier. 
 
Session 4 (1 week after session 3): 
A 20-minute, face to face meeting at the patient’s home, or via telephone. The participant’s 
progress is reviewed, moving on to relapse prevention type strategies. Depending on levels of 
daytime sleepiness and quality of sleep, time in bed may be increased. This session will have 
a large focus on rules for better sleep. This understanding is crucial if the participant is to 
continue with changes made, out with the intervention. Problem solving anticipated potential 
difficulties may be helpful to the participant in continuing with progress. 
 
Participants will then complete the 7 day return to baseline phase, where they will continue to 
complete sleep diaries before meeting with the researcher. At this final meeting, data from 
sleep diaries will be collected. Participants will repeat the outcome measures that they 
completed at the start for comparison along with the satisfaction questionnaire. 
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Appendix 3.1 A copy of the email granting permission for Dr Dr Maria Gardani to share the 
database used in previous studies (Akram et al (2020a, b, c). Dr Gardani was a supervisor of 
this project and a co-author of the previous studies. 
 
 
 
 
Dr. Christoph Scheepers 
Senior Lecturer 
School of Psychology 
University of Glasgow 
62 Hillhead Street 
Glasgow G12 8QB 
Tel.: +44 141 330 3606 
Christoph.Scheepers@glasgow.ac.uk 
Glasgow, April 20, 2020 
 
 
 
 
RE: Share Dataset  
To whom it may concern, 
I understand that Dr Gardani is the local guardian of the data collected on student mental 
health via online survey from UK students, with ethical approval from Sheffield Hallam 
University Research Ethics Committee (Protocol number: ER7368595). I further understand 
that the dataset contains no personally identifying information from the respondents. Given 
that Dr Gardani is the local guardian of the data and named PI on the corresponding ethics 
application, I foresee no issues in her sharing the data with her student for purposes of 
analysis.  
Sincerely, 
Dr Christoph Scheepers 
Dr Christoph Scheepers 
Ethics Officer 
College of Science and Engineering 
University of Glasgow 
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Appendix 3.2 Four conditions of mediation (Baron & Kenny, 1986) 
 
1) predictor variable must significantly predict outcome variable  
2) predictor variable must significantly predict the mediator  
3) mediator must significantly predict the outcome variable  
4) the predictor variable must predict the outcome variable less strongly when the mediator     is 
added to the equation.  
 
 
 
 
 
 
Reference 
Baron, R. M., & Kenny, D. A. (1986). The moderator–mediator variable distinction in social 
psychological research: Conceptual, strategic, and statistical considerations. Journal 
of personality and social psychology, 51(6), 1173. 
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Abstract 
 
Background: Insomnia is a frequently occurring post stroke symptom, with approximately one third 
of sufferers experiencing sleep problems 12 months after stroke. Cognitive Behavioural Therapy, has 
been found to be effective in significantly reducing symptoms of insomnia within the general 
population. Few studies however have been carried out exploring the efficacy of psychological 
interventions for post stroke insomnia.  
Aims: This study aims to explore sleep patterns amongst participants receiving a brief behavioural 
treatment intervention (BBTI) for post stroke insomnia. Additionally it will aim to explore the 
retention and recruitment rate of participants and investigate the potential effectiveness of a brief 
behavioural treatment intervention (BBTI) for post stroke insomnia.  
Methods: Stroke patients (N=6) will be recruited from NHS Outpatient Stroke Services and from 
local charities. Participants meeting the inclusion criteria will complete a batch of sleep and mood 
specific questionnaires before being randomly allocated to 1 of 6 differing duration baseline phases 
(ranging from 5 – 20 days). Once participants have completed their allocated baseline phase they will 
then go on to complete the 4-week BBTI intervention. Finally, participants will complete a 7 day, post 
intervention baseline phase.  Participants will complete sleep diaries throughout during baseline and 
intervention stages. The study will take the form of a multiple baseline ABA single case experimental 
design (SCED), whereby multiple measurements of participant sleep efficiency, sleep duration and 
sleep onset latency will be recorded during the baseline and intervention phases.   
Applications: If the BBTI is found to reduce symptoms of post stroke insomnia, then a larger scale 
research study could be carried out in future.  
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Introduction 
Stroke & its Impact 
Stroke is a major public health concern, causing death and decreased quality of life in people of all 
ages (Zhang et al, 2012). Ischemic stroke - the most common form, occurs when a blockage reduces 
blood flow to the brain causing damage to surrounding cells. The extent of brain injury caused 
depends on the location in which the blockage took place, total duration of blood starvation and the 
ability of neighbouring healthy cells to compensate for the damaged ones (Chen et al, 2014). 
Generally, the less damage caused to brain tissue, the more likely that a full recovery will be made 
(De Meyer et al, 2016). 
 
Post Stroke Insomnia 
As well as the physical consequences, many stroke survivors go on to develop psychological 
difficulties. Meta-analysis suggests that one third of people experience post stroke depression 
(Hackett, Yapa, Parag & Anderson 2005) and one quarter develop post stroke anxiety (Schottke & 
Giabbiconi, 2015), with both disorders gaining research interest and consideration of potential 
treatment options (see Rasquin, Van De Sande, Praamstra, and Van Heugten, 2009 & Broomfield et 
al, 2011). Sleep associated difficulties are also common post stroke, with Kim et al (2017) identifying 
symptoms of insomnia to be present in almost two thirds of patients one-month after stroke. Similarly, 
Glozier et al (2017) found that 34 percent of patients, 12 months post stroke, met the DSM-5 criteria 
for Insomnia. As well as the distress of the symptom itself, insomnia has been identified as a risk 
factor for further stroke, suicide and poorer recovery prognosis (Yang et al, 2017). Despite its high 
prevalence, the impact of insomnia and treatment options amongst stroke survivors has had little 
consideration. 
 
Treatment for Insomnia 
123 
 
There is a wealth of research supporting the efficacy of talking therapies in the treatment of insomnia 
within the general population (Okajima, Komada & Inoue, 2011). Cognitive Behavioural Treatment 
for Insomnia (CBTI) has been reported to be effective in reducing symptoms of insomnia in 70-80% 
of patients, with long-term improvements being documented (Okajima et al, 2011). CBTI can also be 
effective for alleviating insomnia symptoms, in the context of other health conditions including: 
chronic pain (Jungquist et al, 2012), multiple sclerosis (Majendie, Dysch & Carrigan, 2017) heart 
disease (Conley & Redeker, 2015) and cancer (Ritterband et al, 2012). Despite these positive findings, 
trials for the efficacy of CBTI secondary to stroke, to the author’s knowledge, have not been carried 
out. 
 
Brief Behavioural Intervention for Insomnia 
Patients experiencing insomnia alongside a physical health condition may face specific challenges 
that limit the patient's willingness and or ability to attend the traditional 6-8 session intervention. Such 
patients often have multiple commitments and appointments to attend that the prospect of signing up 
to another 8 sessions can be overwhelming. Troxel, Germain & Buysse (2012) developed a BBTI 
manualised protocol, with the intervention spanning 4 treatment sessions. The BBTI is based on core 
CBTI principles for chronic insomnia, as outlined by the National Institute of Health (2005) with the 
significant difference being that the BBTI comprises predominantly of the behavioural components. 
Additionally, the intervention provides patients with a workbook which they take home and can refer 
to throughout the intervention, allowing for continued reinforcement.  
 
This study will aim to deliver a BBTI to participants experiencing post stroke insomnia. The BBTI 
delivered will be based on the manualised BBTI protocol developed by Troxel et al (2012), however 
will be specifically tailored to match the needs of the stroke population, e.g. large print workbooks 
and education on sleep following stroke. 
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Governing bodies state there should be a thorough period of feasibility and pilot testing when 
developing complex treatment interventions (Medical Research Council, 2000). Although research 
within this area has been minimal, a feasibility study looking into the effectiveness of a BBTI for 
insomnia following brain injury was carried out by Zouharova & Gardani (in preparation). This study, 
which took the form of a case series design, recruited nine participants and retained six. Four 
participants demonstrated “clinically significant sleep improvements”, one showed “treatment 
response” and one showed “nonresponse”. Compliance with daily diary completion was high.  
 
This study will follow similar research procedures as the feasibility study described above, exploring 
change in participant sleep efficiency, sleep quality and sleep onset latency post a BBTI, for post-
stroke insomnia.  
 
Aims 
The primary aim of this study is: 
c) To explore change in sleep efficiency amongst participants, post the BBTI, as 
measured by actigraphy data, a series of sleep outcome measures and sleep 
diaries.  
d) To explore change in participant sleep onset latency and sleep duration as 
measured by a series of sleep outcome measures, sleep diaries and actigraphy 
data. 
c)   To explore the recruitment and retention rate of participants taking part in the study. 
The secondary aim of this pilot study is: 
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       a) To determine whether a BBTI for insomnia also reduces symptoms of Anxiety and 
Depression as measured by the Generalised Anxiety Disorder - 7 (GAD-7) and Patient Hospitalised 
Questionnaire – 9 (PHQ-9) respectively.  
 
 
Hypotheses 
There is evidence to suggest that healthy individuals who receive a behavioural intervention in the 
treatment of insomnia experience significant improvements in their insomnia symptoms including 
faster sleep onset, longer sleep duration and improved subjective quality and actual quality of sleep 
(Okajima et al, 2011) even in the context of physical health problems e.g. chronic pain (Pigeon et al, 
2012; Ritterband et al, 2012). 
 
 It is therefore hypothesised that following the completion of the BBTI, participants will experience:  
• An improvement in their sleep efficiency 
• An improvement in their sleep duration 
• An improvement in their sleep latency 
Additionally, given the recruitment and retention rates reported in the feasibility study by Zouharova 
& Gardani (in preparation), it is hypothesised that this study will have a high retention rate of 
participants.  
 
Methods 
Participants 
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The study will recruit approximately 6 participants (rationale for this is described later). All 
participants will have experienced either an ischemic or haemorrhagic stroke and will be over 18 
years.   Due to the intervention requiring participants to complete daily sleep diaries and workbooks, 
participants must exhibit a good level of cognitive functioning. This will be defined as a score of 8 or 
more out of 10 on the Mini-Montreal Cognitive Assessment (MMOCA; Mai et al 2013) at point of 
screening. Stroke induced disability, as measured by the Modified Rankin Scale (Farrell et al, 1991), 
will be recorded for each participant, with this information being obtained from patient records after 
patient consent has been obtained. The Caldicott Guardian will be contacted to seek advice as to the 
correct procedures for obtaining NHS patient records. 
 
Inclusion and Exclusion Criteria 
Eligible participants will meet the DSM-5 criteria for insomnia, with levels of insomnia being 
measured via the Sleep Condition Indicator (SCI; Espie et al, 2014). Participants experiencing other 
sleep disorders e.g. obstructive sleep apnoea, will also be eligible to enter the study, if the disorder is 
effectively managed. Exclusion criteria will include individuals with a diagnosis of dementia, 
epilepsy, an untreated psychotic illness, substance misuse, other neurological disorders and 
medications known to impact on sleep. Additionally, individuals who are aphasic or unable to write 
will be unable to take part, due to the study requiring verbal and written data to be recorded. This 
information will be obtained from looking through the participant record and at point of screening by 
asking the participant for this information. Individuals experiencing chronic pain, will not be able to 
take part in the study since chronic pain could interfere with the intervention and results obtained. At 
point of screening, potential participants will be asked about current levels of pain and completion of 
the Pittsburgh Sleep Quality Index (PSQI; Buysse et al, 1989) will also offer this information. If 
participants report significant levels of pain, despite taking pain medication then they would not be 
eligible to take part in the study. 
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Recruitment Procedures 
Participants will be recruited from a local charity and NHS community stroke services. 
  
Charity recruitment: 'Headway' will be contacted in advance, advising them of the project. The 
researcher will attend events and clubs run by the charity to recruit participants. Potential participants 
will be given information sheets and can voice their interest there and then or return the attached 
freepost ‘note of interest’ slip. The researcher will then arrange to meet with them, on charity 
premises comparing their circumstances to the inclusion/exclusion criteria. Posters will also be put up 
on display within charity premises.  
 
NHS Recruitment: The researcher will present details of the study to NHS Community Stroke 
Services, with potential participants being identified by the Community Stroke Team. Staff will hand 
out information sheets to patients who they have identified as experiencing symptoms of insomnia 
and who may be eligible to participate, with patients returning their note of interest slip or 
alternatively, once made aware of the study, individuals interested in attending can let their key 
worker know and who can contact the researcher directly. The researcher will then arrange to meet 
with them, comparing their circumstances to inclusion/exclusion criteria.  
 
At the brief meeting, after reading the participation sheet, participants will be asked to sign a consent 
form. Consenting participants will be randomly allocated to one of six baseline phases immediately. 
The available baseline phases are; 5, 8, 11, 14, 17 and 20 days.  
 
Measures 
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The following outcome measures will be completed by participants pre-and post BBTI, to obtain 
baseline and intervention related change. 
 
PSQI 
The PSQI will be completed pre and post the intervention to monitor whether there has been a change 
in perceived quality of sleep. A score of 5 or higher indicates poorer sleep. The PSQI has been found 
to have high test-retest validity and reliability (Buysse et al, 1989). 
 
SCI 
The SCI (Espie et al, 2014) will be completed by participants pre and post intervention. The SCI is an 
8 item questionnaire, with a higher total score indicating better sleep. The SCI has been shown to be 
internally consistent, sensitive to change and with high correlation to other sleep screening tools e.g. 
PSQI (Espie et al, 2014). 
 
The Patient Health Questionnaire (PSQ-9)  
 The PHQ-9 (Kroenke & Spitzer, 2001) is a 9-item self-report questionnaire, based on how 
individuals have been feeling over the past two weeks.  Evidence supports reliability and 
validity of the PHQ-9 as a measure of depression in people with physical health difficulties 
(Kroenke & Spitzer, 2001).  
The Generalised Anxiety Disorder (GAD-7) 
The GAD-7 (Spitzer et al, 2006) is a 7 item self-reported anxiety questionnaire. Evidence 
supports the GAD-7 as a measure of anxiety in people with mental health difficulties, with it 
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demonstrating high internal consistency, good validity and sensitivity to change (Shear et al, 
2006). 
Mini Montreal Cognitive Assessment (MMoCA) 
The mini-MOCA is a brief screening tool designed to detect mild forms of cognitive 
impairment, with a total score of 7 or lower out of 10, indicating cognitive impairment. The 
mini-MoCA, is a shorter version of the longer Montreal Cognitive Assessment (MOCA; 
Nasreddine et al, 2005) screening tool, requiring less time for completion. Mai et al (2013) 
found participant scores on the mini-MoCA to be highly correlated with the scores obtained 
on the full version. The mini-MoCA is available to use free of charge and has a completion 
time of approximately 5 minutes. 
 
Sleep Diaries 
Sleep diaries (Espie, 2006) will be completed for the duration of the study. If participants are 
experiencing unstable sleep patterns throughout the baseline period, prior to BBTI intervention then 
this will be adjusted for at point of data analysis. Participants will be asked to complete sleep diaries 
in the morning of each day, with text message reminders being set up to prompt and remind them of 
this. 
A Treatment Acceptability and Credibility Questionnaire, purposely adapted for the study, will be 
used to assess the patient’s overall experience at the end of the intervention. Participants will be asked 
to rate this on a scale from 0-7 with higher numbers indicating higher levels of satisfaction.   
 
Design & Research Procedures 
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This study will take the form of a single case experimental design (SCED), aiming to recruit 6 
participants (rationale is described later). Participants will be randomly allocated, using a random 
number generator (www.randomizer.org), to differing baseline durations (ranging from 5 to 20 days). 
Baseline measurements for sleep onset, total sleep duration and sleep efficiency via sleep diaries and 
actigraphy data will be collected for each participant for the entirety of the baseline phase. Upon 
finishing this phase, participants will then commence the intervention stage of the study before it is 
removed, and participants return to a 7 day baseline phase. Multiple measurements will be recorded 
throughout each phase of the study. The intervention will be delivered across 4, weekly sessions, with 
the first session being a 1-hour long session and the remaining 3 sessions being 20 minutes in 
duration, preferably over the phone or face to face at the participants’ home or charity base.  
Participant adherence and compliance to the protocol will be based on the completion of daily sleep 
diaries. Sleep diary completion will be reviewed at each session.  The first intervention session for 
each participant will take place at room facilities situated at Headway, which Headway have agreed to 
(regardless of point of initial recruitment). For an account of what each of the 4 sessions will entail, 
please see Appendix 1. 
.  
Data Analysis 
Visual analysis of the data will be carried out in the first instance, graphing the data collected and 
visually inspecting any differences between baseline and intervention phases. Historically, it was 
suggested that in SCED designs, visual inspection of the data demonstrated results that statistical tests 
failed to find (Bobrovitz & Ottenbacher, 1998). More recently however, it has been acknowledged 
that visual analysis alone provides some difficulties e.g. collating results for the purposes of meta-
analysis and therefore the increased need for statistical testing that offers results for comparison (Tate 
et al, 2015). Although there is no consensus on which statistical procedure to use in analysing SCED 
data as such (Bobrovitz & Ottenbacher, 1998), the methods available tend to follow the same 
principle whereby they measure the extent of non-overlapping data between differing conditions. Tau-
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U analyses is one statistical method that controls for baseline trend and has an effect size index that is 
reported as being suitable in single case research data where parametric assumptions are often not met 
(Tate et al, 2015). It is unlikely that parametric assumptions would be met in this study and thus this is 
the most likely statistical test of choice. Paired samples t-tests will be used to compare participant 
scores on outcome measures pre and post the intervention. Data on recruitment and retention rates 
will also be reported as will data from the Participant Treatment and Acceptability Questionnaire. 
 
Justification of sample size 
One of the aims of this study is to explore participant recruitment and retention rates to inform future 
larger scale trials. Other than the feasibility study currently under review by Zouharova & Gardani 
(under preparation), which employed a case series design, no other study to the author’s knowledge 
has been carried out in this area. One paper by Krasny-Pacini & Evans (2018) suggested that SCED 
designs typically involve a ‘small number of participants, typically one to three’. Dallery, Cassidy & 
Raiff (2013) state that the number of participants in a SCED study is ‘always more than 1, usually 
around 6 but sometimes as many as 20 participants’. There is no clear guidance as to how many 
participants should be included. Therefore, considering guidance from the literature and the number of 
participants recruited in the study by Zouharova & Gardani (under preparation) this study will aim to 
recruit 6 participants.  
 
Settings and Equipment 
The intervention will take place in charity premises or in the participant’s own home. Workbooks will 
be given to participants and paper copies of outcome measures will also be required for completion at 
the start and at the end of the intervention. 
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Researcher Safety Issues 
Due to the potential incorporation of home visits into the study, the researcher will follow local policy 
guidelines (GG&C Lone working policy, 2014) on lone working. It states that the researcher must 
always advise another staff member of their whereabouts, devising a ‘clock in and clock out’ system 
whereby their location is always accounted for. Additionally, the researcher must always carry a 
mobile telephone with them and only visit homes where wherever possible it has been deemed safe to 
do so. A portable pull point alarm will also be carried by the researcher. 
 
Ethical Issues 
Prescribed sleep time for participants should be carefully considered, especially in 
circumstances where the patient may be more vulnerable due to a lack of sleep e.g. long-
distance driving, or where getting up from their bed in the night may be difficult due to 
mobility difficulties.  
Additionally, ethical approval will be sought from NHS ethics and management approval 
from NHS Greater Glasgow and Clyde (GG&C) Research and Design committee. Data will 
only be used for those purposes approved by ethics committees. All data will be stored 
securely on the GG&C network and within a locked cupboard which only researchers on the 
project will have access to.   
It is possible that participants may become upset when discussing their symptoms. If the participant 
does become upset, the researcher will use their skills as a trainee clinical psychologist to assess risk 
and contain any distress. If there are significant concerns, participant consent will be sought to pass 
this information on to the participant’s GP. Contact details for the researcher and out of hours will be 
incorporated within participation information sheets (See Appendix 2). Participants will be given 
information sheets to read which will explain the purpose and process of participation. It will be made 
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clear that participation is voluntary; participants are free to withdraw from the study at any point, with 
withdrawal having no impact on their overall treatment plan.  
 
Financial Issues 
Workbooks will be needed for each participant to work through, as will sleep diaries and a series of 
outcome measures for completion. (See Appendix 3) for an estimate of cost. 
 
Timetable   
Task Estimated Time to 
Complete 
Estimated Start Date Estimated Completion 
Date 
MRP Draft 4 months September 2017 January 2018 
MRP proposal 6 months January 2018 June 2018 
Finalise Proposal and 
Materials 
2 months June 2018 September 2018 
Ethics Submission 2 months September 2018 October 2018 
Recruit and gather 
data 
7 months October 2018 February 2019 
Data Analysis 2 months February 2019 April 2019 
Final write up 3 months April 2019 July 2019 
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Practical Applications  
If the BBTI is found to reduce participants’ symptoms of insomnia, a larger study could be rolled out 
incorporating larger participant numbers.  
 
The results of the study will be written in the trainee clinical psychologist’s thesis and disseminated to 
Stroke Clinical Psychology Teams and charities as well as at academic meetings and conferences 
across the country 
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